Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review by Peter N Lee & Barbara A Forey
Lee and Forey BMC Cancer 2013, 13:189
http://www.biomedcentral.com/1471-2407/13/189RESEARCH ARTICLE Open AccessIndirectly estimated absolute lung cancer
mortality rates by smoking status and histological
type based on a systematic review
Peter N Lee* and Barbara A ForeyAbstract
Background: National smoking-specific lung cancer mortality rates are unavailable, and studies presenting
estimates are limited, particularly by histology. This hinders interpretation. We attempted to rectify this by deriving
estimates indirectly, combining data from national rates and epidemiological studies.
Methods: We estimated study-specific absolute mortality rates and variances by histology and smoking habit
(never/ever/current/former) based on relative risk estimates derived from studies published in the 20th century,
coupled with WHO mortality data for age 70–74 for the relevant country and period. Studies with populations
grossly unrepresentative nationally were excluded. 70–74 was chosen based on analyses of large cohort studies
presenting rates by smoking and age. Variations by sex, period and region were assessed by meta-analysis and
meta-regression.
Results: 148 studies provided estimates (Europe 59, America 54, China 22, other Asia 13), 54 providing estimates by
histology (squamous cell carcinoma, adenocarcinoma). For all smoking habits and lung cancer types, mortality rates
were higher in males, the excess less evident for never smokers. Never smoker rates were clearly highest in China,
and showed some increasing time trend, particularly for adenocarcinoma. Ever smoker rates were higher in parts of
Europe and America than in China, with the time trend very clear, especially for adenocarcinoma. Variations by time
trend and continent were clear for current smokers (rates being higher in Europe and America than Asia), but less
clear for former smokers. Models involving continent and trend explained much variability, but non-linearity was
sometimes seen (with rates lower in 1991–99 than 1981–90), and there was regional variation within continent
(with rates in Europe often high in UK and low in Scandinavia, and higher in North than South America).
Conclusions: The indirect method may be questioned, because of variations in definition of smoking and lung
cancer type in the epidemiological database, changes over time in diagnosis of lung cancer types, lack of national
representativeness of some studies, and regional variation in smoking misclassification. However, the results seem
consistent with the literature, and provide additional information on variability by time and region, including
evidence of a rise in never smoker adenocarcinoma rates relative to squamous cell carcinoma rates.
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Extensive data are available by age, sex, year and country
on lung cancer mortality rates [1] and on the prevalence
of smoking [2]. There are also a large number of epi-
demiological case-control and prospective studies which
provide estimates of the relative risk of lung cancer by
various aspects of smoking, a recent meta-analysis [3]* Correspondence: PeterLee@pnlee.co.uk
P N Lee Statistics and Computing Ltd, Sutton, Surrey, UK
© 2013 Lee and Forey; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhaving considered data from 287 studies published in
the 1900s. However, mainly because smoking habits are
not usually recorded on death certificates (and would
perhaps be of dubious validity if they were), it is actually
quite difficult to obtain national data on lung cancer
mortality rates by smoking habit. There are some publica-
tions based on prospective studies which present evidence
on variation in lung cancer rates in never smokers by time
(e.g. [4-8]) or by age and sex (e.g. [8-15]), but these dataal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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old, and sometimes based on very few deaths or cases. Data
on rates in former and current smokers and by histological
type are even more limited.
The lack of data on absolute risk of lung cancer by
smoking habit is a serious deficiency as it limits inter-
pretation of the evidence. For example, it is clear that
the relative risk of lung cancer associated with smoking
reported in studies in China is substantially less than
that reported in North American and European studies
[3]. However, this may be because, in China, lung cancer
rates in never smokers are higher and in ever smokers
similar to those in the West, or because rates in ever
smokers are lower, rates in never smokers being similar.
While these two possibilities (among others) imply different
roles of smoking and non-smoking factors, one cannot
readily distinguish them from the currently available evi-
dence. Another example is the case of adenocarcinoma. It
is apparent that rates of adenocarcinoma have been rising
relative to squamous cell carcinoma, a change which has
been linked to the type of cigarette smoked (e.g. [16]), but
there seems to be no good evidence on whether rates of
adenocarcinoma in never smokers have been rising over
time, or stayed constant. Having evidence on this would
seem crucial to the interpretation.
In this paper we use an indirect method for estimating
absolute lung cancer mortality rates by smoking habit based
on combining evidence from epidemiological studies of
smoking and lung cancer and national data on lung cancer
rates. This allows estimation of how mortality rates vary by
sex, country and time period separately for never, former,
current and ever smokers and separately for total lung
cancer, squamous cell carcinoma and adenocarcinoma.
While, as will be discussed, the indirect method has some
limitations, the estimates derived should add useful insight
into the evidence on smoking and lung cancer.
Methods
The indirect method
Overall lung cancer mortality rates
Suppose the population is divided into S + 1 smoking
groups according to smoking habit, with i = 0 referencing
never smokers and i = 1. . .S referencing subdivisions of
ever smokers. For a case-control study, the data can be
expressed in a 2 × (S+1) table, with N1i referring to the
number of cases and N2i to the number of controls in
smoking group i, and N1 and N2 to the total numbers of
cases and controls respectively.
For smoking group i, define p1i as the proportion of
cases (= N1i / N1), p2i as the corresponding proportion of
controls (= N2i / N2), and Ri as the relative risk of lung
cancer compared to never smokers.
Suppose that LW is an estimate of the overall lung
cancer rate in the population from which the study wasdrawn, based on a total of NW cases. Li, the lung cancer
rates by smoking group, can be estimated based on the
following equations:
Ri ¼ p1ip20ð Þ= p10p2ið Þ ð1Þ






These solve directly to give:








The variance of the logarithm of the rate estimate, Li,
can then be estimated approximately as:
varlogLi ¼ 1=NWð Þ þ 1 p1ið Þ=N1p1ið Þ
þ 1 p2ið Þ=N2p2ið Þ ð5Þ
The inverse of var log Li can be used as a weighting
factor in meta-analysis.
In the present work, the formulae are applied either to
estimate lung cancer rates in never and ever smokers or
to estimate lung cancer rates in never, former and
current smokers.
In some studies observed counts may be zero. Here
p1i, p2i and Ri are estimated by adding 0.5 to each cell of
the relevant 2 × (S + 1) table. While this approach is
questionable, estimates derived in this way have very
small weight, so contribute little to meta-analyses.
The method described above is based on data from case-
control studies unadjusted for covariates. It is also applied
to unadjusted data from prospective studies, with N2 and
N2i representing the numbers in the at risk population.
The method can also be applied where there is covariate
adjustment, and the data available consist of the relative
risks, the numbers of cases by smoking group, and the total
number in the at risk population. Here p2i is estimated by:





and formulae (4) and (5) then applied.
Lung cancer rates by histological type
Let zh be the proportion of lung cancer with histological
type h. The overall lung cancer rate for type h is then
given by:
Lh ¼ zhLW ð7Þ
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are estimated using formulae corresponding to formulae
(4a) and (4b) as:
Lhi ¼ Lhph1i=ph2i ð8aÞ
or alternatively as:









Here the superscript h implies that the proportions
and relative risks are estimated from the set of cases and
controls (or at risk) relating to the histological type. In
some case-control studies, the controls are specific to
the histological type, but in others they are common to
all lung cancer cases.
Here the variance of the logarithm of the rates is
estimated as:














Note that, in some studies, histological typing may
only be carried out on a proportion of cases, the rest
being classified as of unknown type. Here N1 in
formula 9 should be replaced by the number of cases for
which typing was carried out.
Application of the method
To apply the indirect method, sex-specific data were
extracted from the International Epidemiological Studies
on Smoking and Lung Cancer (IESLC) database, which
considers all epidemiological prospective and case-control
studies involving over 100 lung cancer cases published in
the last century, and has been described in detail elsewhere
[3]. The data used relate to the relative risk of former,
current and ever smoking, each relative to never smoking.
For each study considered, the data extracted consisted of
the components of the 2 × (S + 1) table and the relative
risks, with the distribution of controls or at-risk estimated,
if not available, using formula (6).
Where there was a choice, relative risks for smoking of
any product were selected if available, or of cigarettes
(or cigarettes only) if not, then selecting the widest available
age and race group, and, for prospective studies, the longest
follow-up. Current and ex smoking relative risks were
constrained to match each other on these selection criteria,
but not necessarily to match the ever smoking relative risk.
Where relevant (e.g. when using relative risks for ever
smoking any product and for current and ex cigarette
smoking) separate versions of the 2 × 2 (never/ever) and
2 × 3 (never/ex/current) tables were used, and the indirectestimate of the never smoker rate that is reported is that
based on the never/ever comparison.
For all lung cancer, we only considered unadjusted
relative risks from case-control studies, and unadjusted
or age-adjusted relative risks from prospective studies,
as these were more directly relevant for comparison with
national mortality rates. (Note that according to the
data-entry protocol for prospective studies in IESLC, an
unadjusted relative risk would not have been entered on
the database if an equivalent age-adjusted relative risk
was available.) However, due to the sparsity of available
data, relative risks adjusted for other potential confounders
were also accepted for squamous cell carcinoma and
adenocarcinoma (preferring the least-adjusted estimates
where there was a choice).
“All lung cancer” was defined (as previously, [3]) as
including at least squamous cell carcinoma and adeno-
carcinoma, “squamous” as including at least squamous
cell carcinoma but not adenocarcinoma, and “adeno” as
including at least adenocarcinoma but not squamous
cell carcinoma. Studies presenting results for squamous
but not adeno, or vice versa, were excluded, as were
studies where the proportion of cases for which typing was
carried out could not be estimated, typically where results
were available only for specific cell types.
Sex-specific estimates of LW, the overall lung cancer
rate, were derived from the WHO mortality database
[1]. This provides data by sex, single years and five year
age groups for an extensive list of countries. For each
epidemiological study, a year was estimated corresponding
to the midpoint of the period of the case-control study or,
for prospective studies, the survival-adjusted midpoint
of the period of follow-up (as further explained in footnote
a of Table 1). If there were no WHO mortality data
corresponding to that year, data for a substitute year
(within 20 years) were used as also shown in Table 1.
Data were not available for India, South Africa, Taiwan,
Turkey or Zimbabwe, so epidemiological data from
these countries were not considered in our analyses.
Table 1 also shows the few cases where data for substitute
countries were used. Data from multi-country studies
were also not considered.
Given that the estimates of LW are of national rates,
the indirect method may be inappropriate for an epi-
demiological study that is based on a special population
or is conducted in an area of high risk. While it is clearly
best if the population considered in the epidemiological
study is nationally representative, it may still give some
useful information if the study is conducted in a major
town in the country. It was decided therefore to consider
all epidemiological study data except where the population
studied was grossly unrepresentative. Studies excluded were
those of occupational groups with a known or possible
lung cancer risk, specific races forming a minority of the
Table 1 Substitute years and countries used
Source of epidemiological data Substitute data taken from
WHO database
Country Yearsa Countryb Yearc ICD codesd
Brazil 1991 Brazil South - -
China 1978–1987 - 1988




Finland 1944–1951 - 1952 -
Germanyf 1936 West Germany 1952 -
Hungary 1953 - 1955 -
Poland 1956 - 1959 -
Uruguay 1991–1995 - 1990 -
USA 1941–1949 - 1950 -
UK 1948 - 1950 -
a For case-control studies, this is the midpoint of the years of the study. For
other studies, it is the midpoint of the years of the baseline phase, plus
f × years of follow-up where the survival factor f is taken as 0.45, 0.425, 0.40,
0.375, 0.35, 0.325 or 0.30 for, respectively, follow-up periods of 1–10, 11–15,
16–20, 21–25, 26–30, 31–35 and 36–40 years. If the follow-up period differs by
smoking status, the value relevant to ever smoking is used.
b Dash indicates that the country for which WHO data were extracted is the
same as the country from which the epidemiological data came.
c Dash indicates that the year for which WHO data were extracted is the same
as the year for which the epidemiological data were relevant.
d Dash indicates that the ICD codes used are A050 for the 6th and 7th
revisions, A051 for the 8th, B101 for the 9th and C33–C34 for the 10th,
corresponding throughout to malignant neoplasm of the trachea, bronchus
and lung. ICD = International Classification of Diseases.
e Additionally includes carcinoma in situ.
f For post-war/pre-unification epidemiological data, WHO data were extracted
for East or West Germany as appropriate to the area where the study was
conducted. For 1991 onwards, WHO data for unified Germany were extracted.
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risk, such as persons with high coronary risk.
Testing the validity of the method with respect to age
While the WHO mortality data are by 5 year age group,
the epidemiological data are typically for the whole age
range considered, though for some studies estimates are
available for less broad age ranges. The question therefore
arises as to the validity of applying estimates of the ratio
Li/LW based on data for a wide age range to overall esti-
mates of LW for a range of 5 year age groups. Given that
the proportion of smokers among both cases and controls
will vary by age, estimates of Li/LW are also likely to vary
by age. However, it seems reasonable to hope that, if one
chooses an age group fairly typical of the average age of
lung cancer cases, then Li/LW based on the total data will
be quite accurate for that age group.
To test this idea, an investigation was carried out using
data from the million person American Cancer Society
Cancer Prevention Study I (CPSI) prospective study starting
in 1959 [9]. This gives lung cancer deaths and person years
by age, sex and smoking status (never/former/current) for
whites. The actual rate of lung cancer (per 100,000 per year)among never smokers by age was estimated and compared
with that predicted based on the overall lung cancer rates
by age and an estimate of L0/LW derived from the total data
ignoring age. Table 2 shows the results for ages 45–49 up
to 85–89 for both sexes. As is evident, the predicted rate
tends to be an overestimate for younger age groups and an
underestimate for older age groups. However, it is reason-
ably accurate for age groups 65–69, 70–74 and 75–79. We
reached similar conclusions based on data from the 1.25
million person US Cancer Prevention Study II prospective
study starting in 1982 [15] (results not shown).
Overall, the correspondence between observed and
predicted rates was best for age 70–74, and it was decided
to use the epidemiological data to estimate Li/LW, and
then apply it to the WHO national data for age 70–74.
However we excluded from consideration epidemiological
studies of young populations, where the upper age limit of
the population studied was less than or equal to 60 years
or where the age range of the population was unknown.
Meta-analysis
Inverse-variance weighted fixed-effect and random-effects
meta-analyses were conducted by standard methods [17],
with heterogeneity quantified by H, the ratio of the
heterogeneity chi-squared to its degrees of freedom,
which is directly related to the statistic I2 [18] by the
formula I2 = 100(H − 1)/H. Meta-analyses were conducted
separately for overall lung cancer rates and also for squa-
mous and for adeno. Estimates were derived for total rates
and for rates by the factors sex, region and grouped year of
study. Tests of variation in rates by individual factor levels
were carried out taking into account the extra-binomial
variability of the data. Thus if H0 and D0 are the heterogen-
eity chi-squared values and degrees of freedom for the total
data (based on a total of M estimates) and Hj and Dj are














(where summation is over the m levels of the factor)
can be considered an approximate F statistic on m-1,
M-m degrees of freedom.
Meta-regression
Inverse-variance weighted regression analyses were
conducted, separately for males and females, to further
assess the effects of region and time period. A continuous
“linear period” variable was defined as 1 = 1930–60,
2 = 1961–70, 3 = 1971–80, 4 = 1981–90, 5 = 1991–99,
and a categorical “continent” variable was defined to take
the levels America, Europe, China and Asia (not China).
Table 2 Lung cancer ratesa in never smokers observed in CPSIb and predicted using the indirect method
Males Females
Age Lung cancers Observed rate Predicted rate Lung cancers Observed rate Predicted rate
45–49 2 2.62 5.54 14 3.69 7.12
50–54 10 6.87 10.02 30 5.01 9.80
55–59 22 11.82 17.65 49 6.94 11.05
60–64 29 17.41 29.49 95 14.39 17.32
65–69 41 31.41 38.67 92 16.78 20.05
70–74 32 33.42 44.28 86 21.01 19.79
75–79 32 52.30 47.88 100 38.39 30.76
80–84 26 85.99 41.21 63 47.58 33.35
85–89 17 48.61 41.51 35 67.05 47.19
Total 215 22.39 22.39 573 14.22 14.22
Note: L0/LW was estimated as 0.1695 for males, and 0.7008 for females.
a mortality rates per 100,000 per year.
b American Cancer Society Cancer Prevention Study I.
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(SEs) for the model with both factors fitted, and the
significances of linear period unadjusted for continent,
continent unadjusted for linear period, linear period
adjusted for continent and continent adjusted for linear
period were tested. Additional analyses tested for the
effects of introducing a fuller 10 level region variable
(Canada, USA, South or Central America, UK, Scandinavia,
West Europe, East Europe, Japan, China, Other Asia),
the fuller 5 level period variable, or interactions between
continent and linear period.
Software
Analysis was carried out using ROELEE version 3.1
(available from P.N. Lee Statistics and Computing Ltd, 17
Cedar Road, Sutton, Surrey SM2 5DA, UK) and Excel 2003.
Results
Studies
Table 3 summarizes features of the 148 studies from 29
countries used for indirect estimation. Reasons for
rejecting 139 studies are given in Additional file 1. The
most common reasons for rejection were no relative risks
available for ever vs never smokers (32 studies), only
combined-sexes results available (45 studies), and study in
an occupational group with a known or possible lung
cancer risk (22 studies). Of the included studies, 7 were
conducted in Canada, 40 in the USA, 7 elsewhere in the
Americas, 17 in the UK, 13 in Scandinavia, 22 elsewhere
in Western Europe, 7 in Eastern Europe, 9 in Japan, 22 in
China (including Hong Kong), and 4 elsewhere in Asia.
There were 120 case-control studies, 25 prospective studies,
two of nested case-control and one of case-cohort design.
78 of the studies provided results for both sexes, 54 for
males only, and 16 for females only. 144 provided results
for total lung cancer, and 54 for squamous and adeno.Estimates
The indirect estimates of the lung cancer rates (per 100,000
per year) and their weights, by smoking habit, location and
study, are given for total lung cancer in Table 4 (males)
and Table 5 (females), for squamous in Table 6 (males) and
Table 7 (females), and for adeno in Table 8 (males)
and Table 9 (females). With some exceptions, the rates
are lowest in never smokers, intermediate in former
smokers and highest in current smokers, consistent
with the general pattern of relative risks.
Meta-analyses
Results of the meta-analyses, overall and by sex, region
and year of study, are shown in Table 10 (never smokers),
Table 11 (ever smokers), Table 12 (current smokers) and
Table 13 (former smokers). In the text below, all rates
mentioned are per 100,000 per year. Estimates given are
random-effects and usually presented to 3 significant
figures together with the 95% confidence interval (CI)
and the number of individual estimates they were based
on, (e.g. 258, 237–278, n = 220).
Never smokers
There are 220 estimates of all lung cancer risk in
never smokers, yielding an overall random-effects estimate
of 45.8 (41.7–50.4). There is marked heterogeneity
(p < 0.001), with estimates varying from a minimum
of 1.7 (SINARA, Thailand, females) to a maximum of
655 (GREGOR, UK, males). Rates are higher (p < 0.001)
in males (56.3, 49.8–63.7, n = 129) than in females (36.0,
31.6–41.0, n = 91). There is also significant (p < 0.001)
variation by region, with rates clearly higher in China
(99.1, 90.2–109, n = 38) than in the other nine regions stud-
ied, where estimates vary from 23.5 to 61.5. The difference
between the sexes is evident in each region, except for other
Asia, where there are few estimates (data not shown). Even
Table 3 Epidemiological studies used for indirect estimates
Region / Countrya Studyb Study designc Yeard Racee Sexf Smoking statusg Producth Lung cancer typei
Canada BANDj CC 1987 all m E Conly(1) q, a
BEST P 1957 all m E, A all
C,X Conly(1) all
1958 f E Conly(1) all
HOROWI CC 1962 all m, f E C(1) all
JAIN CC 1983 all m, f E,C,X C all, q, a
MCDUFF CC 1981 all m E C all
SIEMIA CC 1982 all m E C all, q, a
WIGLE CC 1972 all m, f E,C,X A all
USA ANDERS P 1990 all f E,C,X C all,
E C q, a
BLOT4 CC 1976 wh m E C all
BOUCOT P 1958 all m E, A all
C,X Conly(1) all
BRESLO CC 1951 all m, f E A(2) all
BROSS CC 1963 wh m E, A all
C,X C(1) all
BROWN2j CC 1987 wh m, f E,C,X C q, a
BUFFLE CC 1978 wh m E A all
E C q, a
C,X C(1) all
wh f E A all
wh-hi E C q
wh E C a
wh C,X C(1) all
wh-hi C,X C(1) q, a
BYERS1k CC 1961 wh m E C q, a
CHANG P 1980 all m, f E,C,X C all
CHOW P 1974 wh m E,C,X A all
COMSTO NCC 1987 all m, f E A all
C,X C(1) all
E,C,X C q, a
CPSI P 1962 all m E, C(1) all
wh C,X Conly(1)
all f E,C,X C all
CPSII P 1984 all m E,C,X Conly(1) all
f E,C,X C all
DORGAN CC 1982 wh m, f E A all
wh m E C(1) q, a
all f E C(1) q, a
wh m, f C,X C(1) all
DORN P 1959 wh m E,C,X A all
GOODMA CC 1984 w + o m, f E,C,X C(1) all
GRAHAM CC 1958 wh m E,C,X A all
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Table 3 Epidemiological studies used for indirect estimates (Continued)
HAENSZ CC 1956 all f E A not alv, q + u, a
C,X C(1) not alv, q + u, a
HAMMON P 1953 wh m E A alll, not a, a
HENNEK P 1988 all m E,C,X A all
HORWIT CC 1980 all f E C all
KAISE2 P 1987 all m, f E,C,X Conly(1) all
KELLER CC 1986 wh m, f E,C,X A all
KHUDER CC 1986 all m E,C,X C all, q, a
LOMBA2 CC 1964 all f E C all, q + u, not q + u
LOMBAR CC 1958 all m E A all
C,X C(1) all
MILLER CC 1978 all f E C(1) all
NAM CC 1986 all m, f E,C,X C all
OSANN CC 1985 all m, f E,C,X C all, q, a
OSANN2k NCC 1973 all f E,C,X C KI, KII
PIKE CC 1974 w-hi m, f E A all
SADOWS CC 1941 wh m E A all
SCHWAR CC 1986 wh m, f E,C,X C all
STAYNE CC 1970 all m E A all, q, a
TOUSEY CC 1995 all m, f E, A all
C,X C(1) all
WU CC 1982 wh f E,C,X A q + a
WYNDE2 CC 1963 all m E A all, KI, KII
WYNDE3 CC 1968 all m E,C,X A all, KI, KII
f E A all, KI, KII
WYNDE4 CC 1949 all m E A all, not a, a
f j E A not a, a
WYNDE6 CC 1983 all m E, A all, KI, KII
C,X C(1) all, KI, KII
all f E,C,X C all
wh E C q, a
all C,X C KI, KII
SC America
Uruguay DESTE2 CC 1995 all m E A all, q, a
Uruguay DESTEF CC 1991 all m E,C,X A all
Cuba JOLY CC 1979 all m E,C,X A all
E C(1) q, a
f E,C,X C(1) all
E C(1) q, a
Argentina MATOS CC 1995 all m E,C,X C(1) all, q, a
Argentina PEZZO2 CC 1995 all m E,C,X C all
Argentina PEZZOT CC 1989 all m E,C,X Conly all
E Conly q, a
Brazil WUNSCH CC 1991 all m, f E,C,X C(1) all
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UK ALDERS CC 1980 all m E A alll, q, a
f El MConly(1) all
E A q, a
BENSHL P 1973 all m E,C,X A all
BRETT P 1961 all m E,C,X C all
DARBY CC 1991 wh m, f Em A all
DEAN2 CC 1961 all m, f E,C,X A all
DEAN3 CC 1971 all m E,C,X A all
f E,C,X MConly(1) all
DOLL CC 1950 all m, f E,C,X A all
E A KI, KII
DOLL2 P 1963 all m E,C,X A all
GILLIS CC 1979 all m E,C,X C(1) all
GOLLED CC 1957 all m E C(1) all
GREGOR CC 1977 all m, f E,C,X C all
HOLE P 1979 all m E,C,X A all
MCCONN CC 1948 all m, f E A all
MIGRAN P 1970 all m, f E,C,X A all
PETO P 1966 all m E,C,X A all
STOCKS CC 1954 all m E A all
WILKIN CC 1993 all m, f E C all
Scandinavia
Sweden AXELSS CC 1991 sca m, f E,C,X A all
Sweden DAMBER CC 1975 all m E A all, q, a + al + br
Norway ENGELA P 1970 all m E A all, q, a
C,X C all, q, a
f E A all
C,X C all
Norway KJUUS CC 1981 all m E,C,X A all
Finland KNEKT P 1977 all m E,C,X A all
Finland KOULUM CC 1944 all m E A all
Norway KREYBE CC 1951 all m, f E A all, KI, KII
Denmark LANGE P 1982 all m, f E,C,X A all
Sweden NOU CC 1974 all m, f E A all, q, a
Finland PERNU CC 1951 all m, f E A all
Sweden SVENSS CC 1985 all f E,C,X A all, q, a
Finland TENKAN P 1969 all m E,C,X A all
Iceland TULINI P 1985 all m, f E,C,X A all
W Europe
Switzerland ABELIN CC 1953 all m E A all
Spain AGUDO CC 1991 all f E,C,X Conly(1) all
Spain ARMADA CC 1988 all m E A all
C,X C(1) all
Italy BARBON CC 1983 all m E,C,X A all, q, a
Germany BECHER CC 1986 all m, f E,C,X A all
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Table 3 Epidemiological studies used for indirect estimates (Continued)
f E A q + s, not q + s
France BENHAM CC 1978 all m E A all
C,X Conly(1) all-mix
E,C,X Conly(1) KI, KII
f E C(1) all, KI, KII
Germany BLOHMK CC 1979 all m E,C,X A all
Germany BROCKM CC 1991 wh m, f E C all
Germany DAVEYS CC 1936 all m, f E A all
Netherlands DORANT CCO 1987 all m E,C,X A all
Belgium DROSTE CC 1996 all m E,C,X A all
Germany EBELIN CC 1983 all m E A all
Switzerland GSELL CC 1946 all m E A all
Germany JAHN CC 1991 all m E, A all, q, a
C,X C(1) all, q, a
f E C(1) all
Greece KATSOU CC 1988 all f E,C,X A all, KI, a
Germany KREUZE CC 1993 all m, f E,C,X A all
Italy PASTOR CC 1978 all m E A all
Germany RANDIG CC 1953 all m, f E A all
Italy RONCO CC 1978 all m E A all
France STUCKE CC 1991 all m E,C,X A all
Italy TIZZAN CC 1960 all m, f E,C,X A all
Austria VUTUC CC 1978 all m En C all, KI, KII
f E,C,X C all, KI, KII
E Europe
Hungary ABRAHA P 1984 all m, f E A q + s + a, q, a
Poland JEDRYC CC 1984 all m, f Eo C(1) all,
m E,C,X C(1) q, a
Czechoslovakia KUBIK P 1968 all m E A all
C,X C(1) all
Hungary ORMOS CC 1953 all m E C(1) all, q, a
f E C(1) all
Poland PAWLEG CC 1993 all m E A all
Poland RACHTA CC 1993 all f E,C,X C all
Poland STASZE CC 1956 all m, f E A all, q, a
Japan ESAKI CC 1966 all m, f E C all
GAO2 CC 1990 all m E,C,X C all
HIRAYA P 1972 all m, f E,C,X C(1) all
HITOSU CC 1963 all m, f E,C,X A all
KIHARA CC 1995 jap m E A all
MATSUD CC 1965 all m E C all, q, a
SEGI CC 1950 all m E A all
SOBUE CC 1987 all m, f E,C,X C q + s + l + a, q, a
WAKAI CC 1990 all m, f E,C,X A all, q, a
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Table 3 Epidemiological studies used for indirect estimates (Continued)
China
Hong Kong CHAN CC 1977 all m, f E A all, q + s, a + l
China CHEN2 CC 1983 all m, f E A all
China DU CC 1985 all m, f E A all
China FAN CC 1991 all m, f E C(1) all
China GAO CC 1985 all m, f E,C,X C all
E C q, a
China GENG CC 1988 all m, f E C(1) all
China HU CC 1986 all m, f E C(1) all
China HU2 CC 1978 all m, f E C all
China JIANG CC 1984 all m, f E A all
Hong Kong KOO CC 1982 all f E,C,Xp A all
E A q + s, a + l
Hong Kong LAMTH CC 1985 ch f E A all, q, a
Hong Kong LAMWK CC 1983 ch f E A all, q, a
Hong Kong LAMWK2 CC 1978 all m, f E A q + s + l + a, q, a
China LEI CC 1986 all m, f E A all
China LIU2 CC 1984 all m, f E A all
China LIU3 CC 1986 all m E A all
China LIU4 CC 1987 all m, f E A all
China WANG CC 1992 all m, f E A all
China WUWILL CC 1986 all f E C all, q, a
China XU CC 1986 all m E A all
China XU3 CC 1981 all m, f E A all, KI, KII
China ZHOU CC 1986 all m, f E A all, q, a
Other
S Korea CHOI CC 1987 all m, f E,C,X C all
E C q, a
Singapore MACLEN CC 1973 ch m, f E,C,X C all
Singapore SEOW CC 1998 ch f E C q + s + l + a, q, a
Thailand SIMARA CC 1972 all m, f E C all
a Country not shown if same as region.
b Six character reference codes used in IESLC. See Table two of [3] for associated reference(s).
c CC = case-control, CCO = case-cohort, NCC = nested case-control, P = prospective.
d See footnote a of Table 1.
e ch = Chinese, jap = Japanese, o = oriental, sca = Scandinavian, wh = white, wh-hi = white excluding hispanic.
f m =male, f = female.
g E = ever vs never, C = Current vs never, X = Ex vs never. Studies with no ever vs never relative risk were excluded (see Additional file 1). Except where indicated
below by footnotes l-o, studies shown only as “E” had no current vs never or ex vs never relative risk.
h A = any product, C = cigarettes, MC =manufactured cigarettes. The comparison is between “ever smoked the product” and “never smoked the product” except
where indicated (1) the comparison is with never smokers of any product (i.e. never smokers excluded pipe/cigar only smokers), (2) never smokers included long
term ex smokers.
i Indicates lung cancer types for which results are available, a = adenocarcinoma, all = total lung cancer, alv = alveolar, br = bronchioalveolar, KI = Kreyberg I,
KII = Kreyberg II, l = large cell carcinoma, mix =mixed, q = squamous cell carcinoma, s = small or oat cell carcinoma, u = undifferentiated. Where only one entry is
shown, results are only available for a definition of all lung cancer. Where three entries are shown, the first entry relates to the definition of all lung cancer, the
second to the definition of squamous and the third to the definition of adeno. Where two entries are shown, the two entries relate to the definitions of squamous
and adeno, no results being available for a definition of all lung cancer (as further explained in footnotes j and k).
j All lung cancer not included as only adjusted relative risks available.
k Subsidiary study, results for all lung cancer available from corresponding principal study.
l Current smoking excluded because no ex smoking relative risk available.
m Current and ex smoking excluded because no matching pair of relative risks available.
n Current and ex smoking excluded because only available relative risks did not satisfy age criteria.
o Ex smoking excluded because no current smoking relative risk available.
p Current and Ex based on a subset of the study.
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Table 4 Indirect estimates of mortality ratesa by smoking habit - all lung cancer, males
Region Countryb Studyc
Never smoked Former smoker Current smoker Ever smoker
Rate Weight Rate Weight Rate Weight Rate Weight
Canada BEST 6.2 1.0 70.8 17.6 174.2 252.7 156.6 266.2
HOROWI 77.8 18.6 278.1 300.7
JAIN 59.1 11.0 331.9 103.2 940.7 129.6 591.2 611.6
MCDUFF 83.8 5.3 513.5 407.8
SIEMIA 40.3 11.9 642.0 856.2
WIGLE 43.6 14.2 309.7 108.2 516.2 358.5 444.8 626.4
USA BLOT4 38.8 7.7 563.0 808.7
BOUCOT 5.0 0.5 93.4 9.2 253.2 702.3 202.2 3203.4
BRESLO 17.7 6.1 114.1 1284.3
BROSS 55.7 33.0 325.1 109.0 296.3 582.3 286.8 2219.5
BUFFLE 46.8 4.6 535.2 143.8 474.2 249.1 493.3 2886.8
CHANG 109.5 5.3 435.1 85.4 918.7 54.1 569.6 985.3
CHOW 47.3 6.2 193.2 31.1 688.1 911.6 504.0 4110.0
COMSTO 55.4 3.9 328.5 50.6 967.4 102.3 599.1 882.9
CPSI 32.2 85.2 111.4 335.8 364.3 4374.2 295.9 4642.6
CPSII 52.5 83.4 470.6 1748.1 1124.2 1982.6 673.5 11885.8
DORGAN 55.2 13.5 325.4 191.2 865.7 213.6 542.7 2113.1
DORN 35.0 80.7 142.8 268.2 285.2 2347.6 246.3 3553.1
GOODMA 62.4 10.1 368.6 76.7 1087.0 150.6 673.7 901.0
GRAHAM 26.4 17.6 427.0 94.3 177.8 1078.2 204.7 2385.0
HAMMON 22.5 15.4 145.0 1863.0
HENNEK 128.9 26.5 472.8 109.4 1983.2 139.5 804.2 962.1
KAISE2 143.0 16.5 448.6 36.0 1063.9 122.0 772.5 506.6
KELLER 62.6 267.2 453.0 1313.5 824.9 1455.2 631.8 5420.3
KHUDER 79.1 22.8 594.7 203.6 642.4 316.8 621.1 1889.8
LOMBAR 21.7 12.7 114.7 84.0 218.8 1040.2 192.2 2474.5
NAM 67.3 30.2 885.6 378.3 477.2 268.6 661.8 2244.7
OSANN 40.5 45.3 497.7 255.7 1095.0 564.4 815.1 1838.5
PIKE 86.2 15.1 452.9 1709.4
SADOWS 28.1 15.4 108.6 1047.1
SCHWAR 74.7 99.5 350.7 674.0 1116.9 406.9 613.1 2889.0
STAYNE 134.4 59.2 492.8 862.3
TOUSEY 27.7 4.0 373.0 177.5 1469.6 83.3 612.3 1602.8
WYNDE2 33.4 7.6 281.8 2151.2
WYNDE3 52.7 8.6 198.0 43.4 565.3 288.7 427.0 1141.2
WYNDE4 12.4 11.1 112.8 1139.8
WYNDE6 59.7 80.3 411.1 854.2 903.0 799.7 598.7 5040.3
SC America Uruguay DESTE2 85.1 24.6 570.0 137.9
Uruguay DESTEF 68.3 22.1 412.5 48.7 660.7 108.4 580.5 139.7
Cuba JOLY 35.7 11.4 314.2 72.4 475.2 275.5 434.8 347.2
Argentina MATOS 50.2 10.7 252.7 75.7 426.0 100.6 333.5 437.2
Argentina PEZZO2 20.8 5.8 191.7 123.8 477.6 169.1 312.4 678.0
Argentina PEZZOT 18.2 4.0 185.4 68.4 593.6 113.7 351.5 489.7
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Table 4 Indirect estimates of mortality ratesa by smoking habit - all lung cancer, males (Continued)
Brazil WUNSCH 47.2 12.9 165.4 92.9 267.1 187.5 219.6 657.6
UK ALDERS 74.8 13.9 784.3 2386.1
BENSHL 134.1 6.2 395.6 51.5 1096.9 547.8 791.3 2968.5
BRETT 149.1 6.2 139.3 9.5 585.1 926.6 487.6 1638.2
DARBY 13.1 3.0 648.1 3292.2
DEAN2 131.4 27.0 496.6 51.5 498.6 1009.9 498.4 1703.2
DEAN3 138.4 24.9 602.7 84.7 866.5 1286.8 812.9 2832.9
DOLL 20.4 6.3 100.3 46.1 194.1 1011.7 185.1 1154.3
DOLL2 73.3 19.1 305.8 266.4 805.8 1117.6 561.6 2915.3
GILLIS 117.0 12.3 522.1 128.0 829.5 870.5 733.5 3445.4
GOLLED 67.8 15.1 427.8 1623.4
GREGOR 655.4 6.6 469.0 22.4 848.3 54.6 674.1 319.6
HOLE 141.9 7.2 333.3 27.0 951.4 808.6 768.5 2647.8
MCCONN 148.1 3.7 179.7 552.6
MIGRAN 111.1 4.1 367.3 26.6 852.1 1004.6 738.5 3227.9
PETO 98.3 2.0 75.0 2.0 705.3 1288.0 604.7 2008.3
STOCKS 51.6 42.0 297.1 1793.5
WILKIN 25.3 2.0 636.4 1166.6
Scandinavia Sweden AXELSS 36.6 15.2 167.7 82.5 546.5 99.1 310.9 279.6
Sweden DAMBER 45.6 35.7 333.0 251.1
Norway ENGELA 39.1 6.9 63.4 10.7 225.9 80.2 180.2 87.5
Norway KJUUS 24.2 1.9 151.0 30.9 509.1 72.7 332.4 176.1
Finland KNEKT 121.3 6.2 423.4 20.0 917.7 196.4 771.6 299.4
Finland KOULUM 8.9 4.4 315.2 72.9
Norway KREYBE 3.3 3.6 25.5 9.0
Denmark LANGE 117.3 5.0 283.5 22.0 648.7 343.6 569.7 445.7
Sweden NOU 48.9 6.1 297.8 184.2
Finland PERNU 44.3 40.2 395.6 71.9
Finland TENKAN 46.9 5.0 212.1 23.1 886.8 199.1 687.1 224.2
Iceland TULINI 42.4 4.3 120.0 6.4 440.8 8.0 341.8 8.0
W Europe Switzerland ABELIN 9.1 2.0 284.0 99.8
Spain ARMADA 22.4 3.8 347.6 104.2 548.0 128.5 441.5 757.4
Italy BARBON 50.5 20.7 359.9 120.3 669.9 469.3 557.8 1394.7
Germany BECHER 45.5 2.9 296.8 44.6 678.5 123.6 492.4 840.7
France BENHAM 32.7 34.9 312.7 235.6 492.7 782.3 406.9 2071.8
Germany BLOHMK 188.4 108.5 563.3 221.1 602.4 282.5 584.2 1026.2
Germany BROCKM 375.0 1.0 402.8 1208.1
Germany DAVEYS 26.7 2.8 127.9 369.3
Netherlands DORANT 101.4 6.8 436.4 161.4 1097.6 400.8 750.3 1217.4
Belgium DROSTE 51.9 6.6 360.4 74.6 978.7 308.1 733.1 804.9
Germany EBELIN 105.1 12.5 728.9 196.1
Switzerland GSELL 10.5 1.9 185.4 77.4
Germany JAHN 52.4 16.5 446.3 398.5 516.0 228.2 470.9 1877.1
Germany KREUZE 23.9 22.2 218.2 389.7 1002.0 565.0 520.7 2549.4
Italy PASTOR 72.0 9.6 474.7 656.7
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Table 4 Indirect estimates of mortality ratesa by smoking habit - all lung cancer, males (Continued)
Germany RANDIG 26.8 4.1 134.5 699.6
Italy RONCO 87.3 5.9 445.3 733.7
France STUCKE 3.3 0.5 451.4 183.5 347.7 46.4 416.8 725.4
Italy TIZZAN 54.6 110.5 109.5 153.1 103.4 305.4 105.3 439.2
Austria VUTUC 84.7 18.0 591.0 454.1
E Europe Hungary ABRAHA 69.5 10.2 607.9 755.4
Poland JEDRYC 92.3 43.0 536.1 1022.1
Czechoslovakia KUBIK 28.9 2.0 326.3 8.5 937.3 478.6 813.3 776.8
Hungary ORMOS 21.9 7.1 204.4 113.0
Poland PAWLEG 44.0 4.0 699.6 597.2
Poland STASZE 10.9 4.8 116.0 171.5
Japan ESAKI 75.8 11.4 143.7 375.7
GAO2 69.7 11.4 234.2 71.1 472.3 140.8 357.4 791.2
HIRAYA 46.7 88.6 80.2 16.4 208.6 1645.6 203.5 1675.5
HITOSU 43.9 7.1 199.8 25.5 111.2 315.2 120.7 624.6
KIHARA 69.9 20.4 413.8 531.1
MATSUD 7.5 3.0 160.5 797.2
SEGI 12.9 16.5 22.0 99.9
SOBUE 83.2 28.1 247.5 215.4 354.5 769.2 316.1 2720.6
WAKAI 92.2 9.1 231.2 50.6 382.0 319.2 332.2 1426.3
China HK CHAN 18.3 1.9 504.0 88.1
China CHEN2 76.7 7.9 350.7 274.8
China DU 89.6 22.7 316.3 1155.0
China FAN 148.0 37.0 420.8 619.4
China GAO 89.5 53.1 344.9 76.1 352.0 514.8 350.5 950.9
China GENG 63.5 6.4 380.3 171.7
China HU 172.0 36.6 358.9 142.9
China HU2 119.8 42.2 362.5 415.7
China JIANG 115.7 5.5 315.0 307.7
HK LAMWK2 200.4 15.2 567.8 105.5
China LEI 93.7 34.7 345.0 743.8
China LIU2 76.7 10.2 331.1 557.7
China LIU3 236.7 3.6 285.2 447.1
China LIU4 129.9 1402.0 373.4 2121.6
China WANG 131.8 24.8 457.5 504.6
China XU 131.3 84.4 345.1 823.1
China XU3 63.5 6.4 380.3 171.7
China ZHOU 162.9 55.9 384.9 81.8
Other S Korea CHOI 37.3 11.7 70.1 29.3 192.1 178.9 156.4 241.8
Singapore MACLEN 78.1 3.5 106.5 3.2 297.3 25.4 279.7 26.2
Thailand SIMARA 7.0 17.2 13.9 18.9
a Mortality rates per 100,000 per year for age 70–74 years.
b Not shown if same as region. HK = Hong Kong.
c Six character reference codes used in IESLC. See Table two of [3] for associated reference(s).
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Table 5 Indirect estimates of mortality ratesa by smoking habit – all lung cancer, females
Region Countryb Studyc
Never smoked Former smoker Current smoker Ever smoker
Rate Weight Rate Weight Rate Weight Rate Weight
Canada BEST 17.6 17.7 39.5 3.8
HOROWI 23.7 17.1 43.1 28.4
JAIN 23.0 45.9 82.8 50.1 291.2 88.7 188.1 180.0
WIGLE 24.8 36.6 50.5 9.7 121.9 55.8 101.9 70.4
USA ANDERS 39.2 52.8 257.6 111.4 854.9 517.1 513.9 1754.5
BRESLO 22.6 13.0 31.2 11.1
BUFFLE 18.5 39.2 93.9 64.9 153.1 211.5 132.0 506.0
CHANG 44.0 13.7 94.4 15.2 226.9 62.8 161.9 178.6
COMSTO 37.2 14.1 103.5 9.5 487.8 57.1 333.2 122.8
CPSI 17.9 232.9 24.3 15.4 56.3 195.3 49.8 223.1
CPSII 38.2 204.8 184.6 338.5 471.5 975.6 311.4 2503.8
DORGAN 27.3 93.2 86.0 77.7 332.7 143.5 214.2 382.5
GOODMA 39.1 22.4 239.5 17.1 377.5 46.4 324.4 102.3
HAENSZ 19.7 112.2 32.3 3.3 42.7 57.5 42.4 65.8
HORWIT 18.9 11.7 213.4 135.1
KAISE2 35.2 12.8 166.7 17.0 480.9 166.4 355.1 456.5
KELLER 28.4 440.9 258.0 383.3 412.5 829.7 354.4 1571.4
LOMBA2 25.9 81.1 34.4 220.5
MILLER 20.5 33.2 232.3 515.7
NAM 37.9 59.3 391.3 151.1 366.5 120.4 379.6 512.5
OSANN 26.3 103.3 214.0 94.4 487.3 363.9 392.2 675.2
PIKE 21.7 35.4 105.0 136.3
SCHWAR 33.3 182.4 153.4 201.1 520.5 330.3 331.5 885.6
TOUSEY 27.7 13.5 233.6 63.4 784.1 73.4 434.2 355.1
WU 39.7 29.2 62.1 22.8 258.2 90.4 173.9 237.2
WYNDE3 22.1 24.2 69.0 56.6
WYNDE6 25.2 157.9 138.8 201.4 369.2 397.7 262.4 960.3
SC America Cuba JOLY 37.0 39.6 253.8 14.5 277.1 48.9 272.0 60.1
Brazil WUNSCH 23.6 35.9 78.0 13.4 136.1 31.5 103.8 64.8
UK ALDERS 38.0 67.7 175.9 526.8
DARBY 28.0 24.0 343.2 642.9
DEAN2 36.7 120.7 126.2 1.5 106.3 24.2 107.7 26.6
DEAN3 43.6 52.6 43.7 7.1 144.0 215.4 125.5 259.5
DOLL 25.1 37.9 46.3 4.8 52.3 38.4 51.3 51.2
GREGOR 13.2 1.0 72.5 4.0 189.6 27.1 145.0 90.1
MCCONN 26.9 7.7 74.0 2.2
MIGRAN 18.3 4.5 28.0 1.0 150.7 166.6 132.0 204.7
WILKIN 53.9 12.6 308.2 167.2
Scandinavia Sweden AXELSS 17.5 17.6 52.3 11.0 207.8 51.1 150.7 77.3
Norway ENGELA 15.7 11.0 27.7 5.0 548.1 9.1 51.4 10.9
Norway KREYBE 24.1 9.9 19.3 6.6
Denmark LANGE 36.8 7.3 83.4 8.4 135.0 78.5 124.9 97.9
Sweden NOU 17.9 5.2 127.2 20.7
Finland PERNU 45.1 23.2 84.9 10.3
Sweden SVENSS 15.2 28.7 39.9 16.3 128.3 38.4 92.5 58.1
Iceland TULINI 16.7 3.4 62.5 3.6 318.0 5.0 249.6 5.0
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Table 5 Indirect estimates of mortality ratesa by smoking habit – all lung cancer, females (Continued)
W Europe Spain AGUDO 25.2 127.5 28.8 2.0 67.8 10.1 57.6 13.0
Germany BECHER 20.9 11.2 30.2 4.4 137.8 25.9 93.8 52.8
France BENHAM 17.5 73.4 77.8 25.4
Germany BROCKM 34.7 3.9 69.5 86.5
Germany DAVEYS 28.8 144.4 20.8 0.4
Germany JAHN 32.9 55.8 101.6 78.6
Greece KATSOU 34.7 41.4 96.8 2.8 120.9 15.1 116.5 19.0
Germany KREUZE 32.6 100.2 45.3 22.9 191.4 54.9 123.4 116.5
Germany RANDIG 21.1 27.6 46.9 18.3
Italy TIZZAN 18.1 38.2 66.1 4.9 78.1 10.9 73.8 18.8
Austria VUTUC 31.4 74.7 161.2 26.5 245.7 40.5 209.5 63.4
E Europe Hungary ABRAHA 37.0 34.2 180.6 102.0
Poland JEDRYC 27.8 88.9 222.0 31.3
Hungary ORMOS 38.4 42.1 7.4 1.0
Poland RACHTA 29.3 37.0 112.9 6.1 189.5 32.6 171.7 46.4
Poland STASZE 13.0 25.8 56.2 6.9
Japan ESAKI 29.6 53.7 72.8 17.4
HIRAYA 42.0 436.0 125.0 4.0 98.2 101.1 99.0 105.8
HITOSU 19.6 52.8 164.6 5.6 68.6 38.5 76.5 51.2
SOBUE 49.3 283.7 126.5 23.1 143.1 77.8 138.5 116.9
WAKAI 47.8 95.3 138.6 2.6 175.9 19.1 169.9 23.7
China HK CHAN 106.9 47.9 371.5 32.0
China CHEN2 88.2 25.3 147.4 34.7
China DU 78.5 82.9 151.6 169.0
China FAN 79.6 107.9 312.1 70.7
China GAO 91.5 491.8 284.3 21.6 216.4 71.6 232.1 100.1
China GENG 66.1 71.6 195.6 84.5
China HU 97.0 60.8 168.1 15.5
China HU2 83.8 73.0 157.1 86.4
China JIANG 85.8 22.2 213.4 5.6
HK KOO 114.7 55.0 392.9 7.2 300.0 17.6 317.5 41.1
HK LAMTH 129.0 94.8 491.3 61.7
HK LAMWK 117.5 58.8 484.0 30.8
HK LAMWK2 119.8 46.5 384.1 31.0
China LEI 67.3 101.2 234.7 63.1
China LIU2 64.1 50.0 273.3 24.3
China LIU4 81.7 994.6 359.5 761.3
China WANG 115.4 303.6 461.7 4.1
China WUWILL 80.4 345.3 178.0 282.6
China XU3 60.5 16.1 243.4 12.5
China ZHOU 95.5 125.7 211.8 8.1
Other S Korea CHOI 32.4 80.7 140.0 2.0 39.6 8.8 51.2 11.9
Singapore MACLEN 40.4 6.3 32.2 1.8 95.9 5.9 84.7 6.1
Singapore SEOW 90.8 35.2 501.6 10.8
Thailand SIMARA 1.7 7.5 4.0 5.6
a Mortality rates per 100,000 per year for age 70–74 years.
b Not shown if same as region. HK = Hong Kong.
c Six character reference codes used in IESLC. See Table two of [3] for associated reference(s).
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Table 6 Indirect estimates of mortality ratesa by smoking habit – squamous lung cancer, males
Region Countryb Studyc
Never smoked Former smoker Current smoker Ever smoker
Rate Weight Rate Weight Rate Weight Rate Weight
Canada BAND 5.7 6.8 213.9 766.4
JAIN 9.9 2.0 123.8 43.4 379.8 75.3 232.9 179.5
SIEMIA 9.3 2.9 270.8 358.2
USA BROWN2 24.1 184.9 214.7 1157.1 338.0 1108.7 268.1 2821.2
BUFFLE 13.8 3.4 194.2 222.7
BYERS1 26.9 22.2 223.4 514.8
COMSTO 26.7 2.0 147.5 17.9 302.2 27.4 215.1 60.6
DORGAN 14.3 4.0 269.9 526.3
HAMMON 7.9 4.0 127.8 1033.6
KHUDER 30.9 8.7 207.2 51.5 266.0 101.2 241.7 221.4
OSANN 7.2 8.0 164.9 97.3 341.9 219.5 259.0 402.9
STAYNE 51.0 22.2 177.0 164.2
WYNDE2 10.9 2.9 215.5 804.0
WYNDE3 17.6 3.0 148.5 33.3 425.9 203.8 321.4 482.9
WYNDE4 8.3 7.6 106.6 1030.8
WYNDE6 19.9 28.2 257.3 582.5 553.3 616.0 369.8 2394.8
SC America Uruguay DESTE2 18.3 3.6 240.9 124.4
Cuba JOLY 5.0 2.0 155.7 160.4
Argentina MATOS 14.3 3.0 48.7 14.2 131.4 32.9 87.3 57.7
Argentina PEZZOT 2.2 0.5 140.9 109.4
UK ALDERS 24.8 1.8 364.3 290.6
DOLL 12.1 2.9 157.5 943.0
Scandinavia Sweden DAMBER 15.1 12.7 178.3 143.0
Norway ENGELA 12.5 2.8 51.5 19.1 136.7 25.4 80.9 38.6
Norway KREYBE 1.7 2.3 21.3 8.9
Sweden NOU 6.1 2.0 167.0 63.5
W Europe Italy BARBON 13.8 5.9 122.1 50.7 242.0 189.5 198.6 314.1
France BENHAM 18.2 23.3 231.0 206.4 361.4 609.7 314.3 1174.6
Germany JAHN 8.7 3.0 187.5 180.9 225.6 124.5 201.3 462.2
Austria VUTUC 75.8 16.2 532.6 403.3
E Europe Hungary ABRAHA 2.8 0.5 260.5 187.3
Poland JEDRYC 18.9 5.9 131.0 42.3 413.5 225.6 291.1 346.4
Hungary ORMOS 6.5 2.0 66.3 29.5
Poland STASZE 1.1 0.5 62.1 108.3
Japan MATSUD 2.6 1.0 102.4 214.8
SOBUE 7.2 2.9 102.3 105.9 142.1 304.7 127.9 562.4
WAKAI 18.4 2.0 115.6 26.1 181.5 108.3 159.7 188.8
China HK CHAN 18.3 1.9 278.9 65.5
China GAO 21.6 12.6 188.5 393.4
HK LAMWK2 43.6 4.5 300.2 76.2
China XU3 30.6 2.9 181.4 51.7
China ZHOU 71.8 41.0 225.2 73.9
Other S Korea CHOI 17.2 5.7 93.7 150.6
a Mortality rates per 100,000 per year for age 70–74 years.
b Not shown if same as region. HK = Hong Kong.
c Six character reference codes used in IESLC. See Table two of [3] for associated reference(s).
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Table 7 Indirect estimates of mortality ratesa by smoking habit – squamous lung cancer, females
Region Countryb Studyc
Never smoked Former smoker Current smoker Ever smoker
Rate Weight Rate Weight Rate Weight Rate Weight
Canada JAIN 2.7 5.9 21.4 18.6 77.3 49.2 49.7 78.7
USA ANDERS 4.8 5.1 121.8 78.5
BROWN2 5.3 115.8 103.0 225.7 110.5 304.6 107.2 592.2
BUFFLE 2.5 3.0 31.1 17.3 32.5 45.2 32.0 93.9
COMSTO 1.5 0.5 14.5 1.4 107.6 14.4 70.2 17.8
DORGAN 5.5 24.3 61.2 206.3
HAENSZ 10.7 51.8 19.5 2.3 33.0 46.2 32.3 51.9
LOMBA2 5.6 15.3 23.8 124.6
OSANN 3.3 12.1 44.3 26.4 106.1 114.1 84.6 155.9
OSANN2 3.7 6.8 11.4 5.5 77.5 47.9 56.9 77.8
WYNDE3 5.5 5.2 37.5 27.8
WYNDE4 8.6 12.9 50.2 19.7
WYNDE6 2.7 12.4 26.9 98.4 79.5 186.9 83.8 169.4
SC America Cuba JOLY 4.3 5.8 79.1 31.7
UK ALDERS 9.8 7.1 59.7 91.9
DOLL 16.0 17.4 38.5 33.7
Scandinavia Norway KREYBE 2.4 2.5 3.2 1.8
Sweden NOU 2.1 1.1 14.6 1.6
Sweden SVENSS 2.0 4.8 8.0 5.1 37.9 23.3 25.8 31.0
W Europe Germany BECHER 5.4 2.1 57.4 33.5
France BENHAM 10.6 36.4 60.0 17.8
Greece KATSOU 11.3 13.6 54.3 2.1 72.4 11.8 69.1 14.6
Austria VUTUC 11.8 35.0 130.0 24.0 216.4 38.8 179.4 60.0
E Europe Hungary ABRAHA 7.5 7.2 40.3 18.3
Poland STASZE 0.2 0.3 7.0 0.8
Japan SOBUE 4.1 14.5 27.1 6.5 42.8 27.1 38.5 35.1
WAKAI 2.9 3.1 27.7 0.8 80.0 11.3 71.5 12.8
China HK CHAN 24.2 16.2 155.7 22.5
China GAO 12.8 54.4 74.3 48.3
K KOO 41.7 26.3 172.9 31.5
HK LAMTH 20.7 23.2 168.0 16.8
HK LAMWK 11.0 6.8 115.5 14.5
HK LAMWK2 27.6 13.7 179.3 21.1
China WUWILL 15.5 59.3 65.0 134.9
China XU3 9.9 2.1 168.1 9.9
China ZHOU 23.6 37.9 90.1 7.0
Other S Korea CHOI 4.3 10.1 29.6 8.2
Singapore SEOW 9.9 8.5 172.7 8.1
a Mortality rates per 100,000 per year for age 70–74 years.
b Not shown if same as region. HK = Hong Kong.
c Six character reference codes used in IESLC. See Table two of [3] for associated reference(s).
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Table 8 Indirect estimates of mortality ratesa by smoking habit – adeno lung cancer, males
Region Countryb Studyc
Never smoked Former smoker Current smoker Ever smoker
Rate Weight Rate Weight Rate Weight Rate Weight
Canada BAND 40.7 42.8 166.8 626.5
JAIN 19.7 3.9 79.0 28.5 213.0 48.5 136.1 98.1
SIEMIA 15.5 4.8 123.2 162.4
USA BROWN2 20.4 153.9 152.7 791.0 187.8 628.3 167.6 1700.3
BUFFLE 25.8 5.3 115.9 115.2
BYERS1 8.6 7.0 35.1 50.3
COMSTO 26.7 2.0 112.8 13.5 335.8 30.5 210.2 58.7
DORGAN 17.7 4.8 85.1 126.1
HAMMON 3.9 2.0 13.0 31.8
KHUDER 24.1 6.8 192.8 52.5 197.6 65.1 195.4 165.0
OSANN 12.6 14.0 160.1 94.7 300.4 195.5 234.7 360.2
STAYNE 16.2 7.0 58.5 46.2
WYNDE2 18.2 4.8 30.4 47.2
WYNDE3 35.2 5.8 49.5 11.7 139.5 59.1 105.6 83.7
WYNDE4 4.1 3.9 6.2 35.9
WYNDE6 39.8 54.9 153.8 371.2 349.7 458.4 228.8 1297.1
SC America Uruguay DESTE2 26.2 4.0 112.5 78.9
Cuba JOLY 12.5 4.9 55.2 65.8
Argentina MATOS 24.5 5.0 117.6 33.8 187.6 45.6 150.3 113.3
Argentina PEZZOT 13.7 3.0 99.9 71.6
UK ALDERS 14.2 1.8 101.2 43.1
DOLL 7.1 1.9 6.4 31.9
Scandinavia Sweden DAMBER 17.6 11.7 42.3 41.6
Norway ENGELA 14.1 4.4 15.5 9.3 99.8 13.0 32.9 16.8
Norway KREYBE 1.7 2.3 4.3 7.6
Sweden NOU 12.3 3.5 54.7 16.4
W Europe Italy BARBON 16.1 6.9 88.4 38.1 129.9 105.0 114.9 167.4
France BENHAM 8.4 7.7 20.4 18.1 35.0 60.3 30.1 96.4
Germany JAHN 23.3 7.7 123.7 122.5 109.1 67.3 117.0 237.2
Austria VUTUC 8.9 2.0 58.3 39.5
E Europe Hungary ABRAHA 45.3 8.1 108.6 65.7
Poland JEDRYC 22.0 6.7 56.3 19.0 110.2 54.6 85.5 72.2
Hungary ORMOS 1.3 0.4 8.8 3.6
Poland STASZE 1.0 0.5 8.9 18.8
Japan MATSUD 1.3 0.5 22.4 26.2
SOBUE 64.7 23.1 98.9 102.8 130.3 279.1 119.1 512.0
WAKAI 73.8 7.4 98.5 22.4 158.3 91.4 138.5 150.4
China HK CHAN 4.5 0.5 136.0 40.8
China GAO 69.7 38.0 108.1 203.5
HK LAMWK2 130.7 11.2 121.0 40.6
China XU3 30.6 2.9 134.9 35.5
China ZHOU 65.8 39.4 86.0 54.8
Other S Korea CHOI 20.1 6.6 26.9 45.2
a Mortality rates per 100,000 per year for age 70–74 years.
b Not shown if same as region. HK = Hong Kong.
c Six character reference codes used in IESLC. See Table two of [3] for associated reference(s).
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Table 9 Indirect estimates of mortality ratesa by smoking habit – adeno lung cancer, females
Region Countryb Studyc
Never smoked Former smoker Current smoker Ever smoker
Rate Weight Rate Weight Rate Weight Rate Weight
Canada JAIN 10.6 22.6 16.6 14.9 65.9 44.5 41.5 68.4
USA ANDERS 31.4 36.8 191.4 143.6
BROWN2 18.9 413.3 132.1 336.8 132.1 336.8 130.7 748.8
BUFFLE 9.8 20.0 32.7 17.5 46.7 61.6 39.6 130.4
COMSTO 25.7 8.5 63.4 5.6 163.5 21.4 123.2 33.3
DORGAN 13.2 48.4 51.4 217.4
HAENSZ 9.0 42.4 12.8 1.7 9.8 15.3 10.0 17.4
LOMBA2 20.2 57.9 10.7 47.2
OSANN 12.9 48.7 76.4 42.6 157.6 159.9 129.3 235.9
OSANN2 11.1 19.0 19.8 6.3 38.6 25.2 33.0 39.6
WYNDE3 16.6 17.3 31.5 23.0
WYNDE4 11.2 18.4 6.7 2.1
WYNDE6 13.0 62.4 65.6 126.3 156.5 265.1 178.5 250.4
SC America Cuba JOLY 17.8 21.7 54.4 24.4
UK ALDERS 8.2 8.6 29.5 24.4
DOLL 3.3 4.5 6.4 6.7
Scandinavia Norway KREYBE 21.7 9.6 16.1 5.9
Sweden NOU 29.8 15.6 26.3 6.8
Sweden SVENSS 8.8 18.5 16.0 9.0 34.3 22.1 26.9 31.8
W Europe Germany BECHER 2.9 1.0 31.7 17.4
France BENHAM 5.8 18.2 14.0 3.9
Greece KATSOU 24.3 28.2 40.7 1.8 45.2 9.1 44.4 11.3
Austria VUTUC 19.6 52.8 31.2 9.5 29.2 12.0 30.1 21.1
E Europe Hungary ABRAHA 17.2 17.2 45.1 20.7
Poland STASZE 8.6 13.9 9.4 1.0
Japan SOBUE 39.7 204.0 77.5 16.1 56.1 34.8 62.0 55.6
WAKAI 44.0 81.8 110.9 2.3 48.0 7.5 58.1 10.8
China HK CHAN 50.9 29.4 99.1 17.4
China GAO 64.3 305.7 69.8 46.1
HK KOO 60.0 35.0 96.4 22.3
HK LAMTH 100.4 73.4 187.6 31.3
HK LAMWK 94.0 49.2 198.0 20.5
HK LAMWK2 75.5 32.8 133.2 17.4
China WUWILL 45.7 184.2 62.8 124.3
China XU3 34.5 7.9 44.8 3.5
China ZHOU 54.0 77.0 77.2 6.8
Other S Korea CHOI 20.9 50.9 13.5 4.3
Singapore SEOW 66.1 30.8 156.2 7.8
a Mortality rates per 100,000 per year for age 70-74 years.
b Not shown if same as region. HK = Hong Kong.
c Six character reference codes used in IESLC. See Table two of [3] for associated reference(s).
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Table 10 Meta-analyses of indirect estimates of lung cancer mortality rates in never smokers
Sex Region Period Statistica All lung cancerb Squamousc Adenod
All All All n 220 81 81
Rate 45.8 (41.7–50.4) 10.5 (8.6–12.8) 21.2 (17.9–25.1)
H,PH 23.53, <0.001 9.18, <0.001 16.21, <0.001
Male n 129 43 43
Rate 56.3 (49.8–63.7) 15.5 (12.2–19.8) 20.2 (15.8–25.8)
Female n 91 38 38
Rate 36.0 (31.6–41.0) 7.6 (6.0–9.7) 22.1 (17.5–28.0)
Betweene PB <0.001 <0.001 NS
Canada n 10 4 4
Rate 34.5 (24.3–48.9) 5.4 (2.9–9.7) 19.4 (8.5–44.4)
USA n 54 25 25
Rate 37.6 (32.6–43.3) 9.3 (6.5–13.4) 16.1 (13.5–19.1)
SC Americaf n 9 5 5
Rate 40.2 (28.4–56.7) 7.9 (3.8–16.2) 18.0 (13.2–24.7)
UK n 26 4 4
Rate 61.5 (46.8–80.8) 14.2 (9.9–20.4) 6.7 (3.8–11.6)
Scandinaviag n 20 7 7
Rate 29.6 (21.9–40.0) 4.4 (1.9–10.2) 13.2 (7.8–22.6)
W Europeh n 31 8 8
Rate 38.2 (29.3–49.8) 14.9 (8.9–24.9) 13.1 (8.3–20.7)
E Europei n 11 6 6
Rate 32.3 (22.3–46.8) 6.6 (2.8–15.5) 14.7 (7.3–29.8)
Japan n 14 5 5
Rate 42.5 (34.5–52.4) 5.0 (2.8–8.7) 47.2 (35.3–63.0)
Chinaj n 38 14 14
Rate 99.1 (90.2–108.8) 23.7 (16.8–33.4) 64.8 (54.6–76.9)
Other Asiak n 7 3 3
Rate 23.5 (9.9–55.8) 8.7 (3.9–19.2) 31.0 (13.1–73.4)
Betweene PB <0.001 <0.05 <0.001
1930–60 n 36 11 11
Rate 24.1 (20.2–28.9) 7.6 (5.1–11.2) 6.9 (4.6–10.4)
1961–70 n 26 8 8
Rate 41.2 (31.2–54.4) 12.6 (6.0–26.7) 17.0 (12.6–22.9)
1971–80 n 46 18 18
Rate 50.2 (39.8–63.2) 12.7 (8.6–18.9) 18.1 (11.8–27.8)
1981–90 n 81 40 40
Rate 59.5 (52.1–67.9) 10.2 (7.6–13.6) 29.0 (23.4–35.8)
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Table 10 Meta-analyses of indirect estimates of lung cancer mortality rates in never smokers (Continued)
1991–99 n 31 4 4
Rate 44.4 (33.9–58.0) 11.6 (7.3–18.4) 33.9 (17.6–65.3)
Betweene PB <0.001 NS <0.01
a n = number of estimates combined, Rate = random-effects meta-analysis lung cancer mortality rate per 100,000 per year for age 70-74 years (95% CI),
H = heterogeneity per degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.01, p < 0.05, p < 0.1 or NS (p ≥ 0.1), PB = probability
value for heterogeneity between levels (see Methods) similarly expressed.
b All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
c Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
d Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
e Heterogeneity between levels of factor considered.
f Including Argentina, Brazil, Cuba, Uruguay.
g Including Denmark, Finland, Iceland, Norway, Sweden.
h Including Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Switzerland.
i Including Czechoslovakia, Hungary, Poland.
j Including China, Hong Kong.
k Including Singapore, South Korea, Thailand.
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http://www.biomedcentral.com/1471-2407/13/189for China, where rates in females are particularly high
(89.8, 82.5–97.8, n = 20), rates are still higher in males
(119, 104–136, n = 18). While there is a significant
(p < 0.001) evidence of variation by period of study, the
trend it not simple, with rates starting low in 1930–1960,
increasing to 1981–1990 and then falling.
There are 81 estimates for squamous in never smokers,
with the overall rate estimate 10.5 (8.6–12.8), 23% of the
total lung cancer risk. There is a clearly (p < 0.001) higher
risk for males (15.5, 12.2–19.8, n = 43) than for females
(7.6, 6.0–9.7, n = 38). The variation by region is less clear
(p < 0.05), though rates were again highest for China not
only overall (23.7, 16.8–33.4, n = 14), but also separately in
males (35.7, 18.3–69.6, n = 5) and females (20.1, 15.0–26.8,
n = 9). There is no significant variation by period (p ≥ 0.1)
with rates quite similar between 1961–70 and 1991–98.
The 81 estimates for adeno in never smokers gave an
estimate of 21.2 (17.9–25.1), higher than that for squa-
mous, forming 46% of the total lung cancer risk. Here
there is no evidence of a difference between the sexes
(p ≥ 0.1) with rates 20.2 (15.8–25.8, n = 43) for males and
22.1 (17.5–28.0, n = 38) for females. Rates clearly vary by
region, being higher in China (64.8, 54.6–76.9, n = 14),
Japan (47.2, 35.3–63.0, n = 5) and other Asian countries
(31.0, 13.1–73.4) than in other regions, where rate esti-
mates vary from 6.7 to 19.4. Rates in China and in Japan
are quite similar in males and females (data not shown).
There is also evidence of variation by period (p < 0.01),
with rates rising steadily from 6.9 (4.6–10.4, n = 11) for
1930–60, to 33.9 (17.6–65.3, n = 4) for 1991–98.
Ever smokers
The estimated rates shown in Table 11 for ever smokers
are substantially higher than those for never smokers in
Table 10. Thus the all lung cancer rate for ever smokers
of 258 (240–278, n = 220) is 5.6 times the rate for never
smokers, while those of 117 (103–133, n = 81) for
squamous and 58.5 (50.1–68.2, n = 81) for adeno are,
respectively 11.1 times and 2.8 times the correspondingrates for never smokers. Whereas, in never smokers, rates
are about twice as high for adeno than for squamous, the
reverse is true for ever smokers, with rates for squamous
double those for adeno.
The difference between the sexes is clearer for ever
smokers than for never smokers. For ever smokers, rates
in males are 147% higher than in females for all lung
cancer (p < 0.001), 185% higher for squamous (p < 0.001)
and 37% higher for adenocarcinoma (p < 0.01). For never
smokers the corresponding excesses in males compared
to females are 56% for all lung cancer and 104% for
squamous, with no excess seen for adenocarcinoma.
There is clear variation (p < 0.001) in ever smoker all
lung cancer rates by region. However, while rates are, as
for never smokers, high in China (316, 292–342, n = 38),
they are similar in the UK (352, 295–422, n = 26) and al-
most as high in South and Central America (320, 254–404,
n = 9) and in the USA (287, 246–334, n = 341). Variation by
region in ever smoker rates is not significant (p ≥ 0.1)
for squamous, but is significant (p < 0.05) for adeno.
Rates in China remain relatively high for both lung
cancer types, though as for all lung cancer, some regions
have similar rates.
There is a tendency for rates to rise over time, particularly
for all lung cancer (p < 0.001) and adeno (p < 0.001) and
evident to some extent for squamous (p < 0.01). The rise is
particularly striking for adeno, where rates are 8.2, 33.8,
55.7, 97.9 and 127 for the five successive periods studied.
Trends in rates for never and ever smokers by region
Figure 1 (males) and Figure 2 (females) plot the individual
rate estimates for all lung cancer by study midpoint year
separately for the four major regions: America, Europe,
China and other Asian countries. Estimates for ever and
never smokers are distinguished by colour. A number of
features of the results are clear, some already referred to
in the preceding sections. These include the higher rates
in ever smokers than never smokers; the higher rates
in never smokers in China than elsewhere; the clear
Table 11 Meta-analyses of indirect estimates of lung cancer mortality rates in ever smokers
Sex Region Period Statistica All lung cancerb Squamousc Adenod
All All All n 220 81 81
Rate 258.3 (239.6–278.3) 117.0 (102.7–133.3) 58.5 (50.1–68.2)
H,PH 244.49, <0.001 83.73, <0.001 52.65, <0.001
Male n 129 43 43
Rate 365.9 (334.4–400.4) 185.9 (163.1–211.9) 67.1 (55.3–81.4)
Female n 91 38 38
Rate 148.2 (130.5–168.4) 65.2 (54.3–78.4) 49.1 (38.2–63.1)
Betweene PB <0.001 <0.001 <0.01
Canada n 10 4 4
Rate 223.4 (153.2–325.7) 162.8 (102.0–259.8) 104.7 (64.3–170.5)
USA n 54 25 25
Rate 286.7 (246.0–334.2) 115.9 (90.9–147.6) 63.4 (48.3–83.2)
SC Americaf n 9 5 5
Rate 320.1 (253.8–403.7) 131.9 (92.6–188.0) 88.7 (60.2–130.6)
UK n 26 4 4
Rate 352.3 (294.5–421.6) 108.7 (52.4–225.7) 18.9 (4.5–79.8)
Scandinaviag n 20 7 7
Rate 199.9 (149.0–268.2) 43.8 (21.2–90.6) 24.6 (14.9–40.4)
W Europeh n 31 8 8
Rate 245.0 (203.3–295.3) 160.8 (112.3–230.4) 46.9 (28.6–76.7)
E Europei n 11 6 6
Rate 255.4 (178.3–365.9) 89.4 (44.4–180.2) 30.2 (13.2–68.9)
Japan n 14 5 5
Rate 151.0 (115.5–197.6) 94.5 (69.1–129.3) 69.2 (43.3–110.6)
Chinaj n 38 14 14
Rate 315.6 (291.6–341.5) 156.5 (117.5–208.4) 106.5 (87.4–129.7)
Other Asiak n 7 3 3
Rate 67.6 (26.1–174.8) 79.5 (36.7–172.2) 39.0 (11.2–135.7)
Betweene PB <0.001 NS <0.05
1930–60 n 36 11 11
Rate 120.7 (103.7–140.6) 59.6 (45.8–77.6) 8.2 (6.5–10.4)
1961–70 n 26 8 8
Rate 203.4 (161.2–256.8) 110.7 (68.4–179.1) 33.8 (19.4–58.7)
1971–80 n 46 18 18
Rate 285.5 (246.1–331.2) 143.5 (101.9–202.2) 55.7 (42.1–73.6)
1981–90 n 81 40 40
Rate 340.6 (312.8–370.9) 125.3 (105.4–148.9) 97.9 (84.7–113.2)
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Table 11 Meta-analyses of indirect estimates of lung cancer mortality rates in ever smokers (Continued)
1991–99 n 31 4 4
Rate 326.5 (283.8–375.5) 165.6 (111.5–246.1) 126.7 (108.4–148.0)
Betweene PB <0.001 <0.01 <0.001
a n = number of estimates combined, Rate = random-effects meta-analysis lung cancer mortality rate per 100,000 per year for age 70–74 years (95% CI),
H = heterogeneity per degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.01, p < 0.05, p < 0.1 or NS (p ≥ 0.1), PB = probability
value for heterogeneity between levels (see Methods) similarly expressed.
b All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
c Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
d Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
e Heterogeneity between levels of factor considered.
f Including Argentina, Brazil, Cuba, Uruguay.
g Including Denmark, Finland, Iceland, Norway, Sweden.
h Including Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Switzerland.
i Including Czechoslovakia, Hungary, Poland.
j Including China, Hong Kong.
k Including Singapore, South Korea, Thailand.
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http://www.biomedcentral.com/1471-2407/13/189tendency for ever smoker rates to rise with time in
America and Europe, any corresponding time trend in
China not being evident perhaps due to the time range
studied there being much narrower; and the lack of
any very clear time trend in never smokers, except that
rates before 1960 are lower.
Figure 3 (males) and Figure 4 (females) plot the
individual rate estimates for never smokers by study
midpoint year for the same four regions, with estimates
for squamous and adeno distinguished by colour. Figure 5
(males) and Figure 6 (females) similarly plot results for ever
smokers. In never smokers, rates are generally higher for
adeno than squamous, with the reverse being true for ever
smokers. While never smokers adeno rates are particularly
high in China, (most clearly seen for females), never smoker
squamous rates are also higher in China than elsewhere.
For both never and ever smokers, evidence of an increasing
time trend is stronger for adeno than squamous.
Current smokers
The estimated rates shown in Table 12 for current
smokers are higher than the corresponding rates for ever
smokers in Table 11. Thus the rates are 370 (328–417, n
= 116) for all lung cancer, 149 (115–193, n = 28) for
squamous and 102 (81.3–128, n = 28) for adeno, which
are, respectively, 43%, 27% and 75% higher than the
corresponding rates for ever smokers. Rates in current
smokers are clearly higher in males than in females for
all lung cancer (p < 0.01), squamous (p < 0.001) and
adeno (p < 0.05): For squamous the rate in males of 275
(224–338, n = 15) is almost 4 times that for females of
71.9 (54.9–94.2, n = 13).
For all lung cancer, there is significant (p < 0.05)
variation by region. Rates are highest in the USA
(477, 391–582, n = 40) and exceed 300 in all European
and American regions, but are lower in Asia. Since there
are only 28 estimates for current smokers by lung cancer
type, with 13 from the USA, there are insufficient data tosee a clear pattern by region. No significant relationship
was noted (p ≥ 0.1) for either squamous or adeno.
For all lung cancer, there was significant (p < 0.001) vari-
ation by period, with the rates of 141 (113–176, n = 10) for
1930–60, rising to a high of 457 (394–532, n = 49) for
1981–90. Clear patterns by period are not evident by lung
cancer type, partly because 19 of the 28 estimates are for
the period 1981–90. A significant relationship was not seen
for squamous (p ≥ 0.1), but was seen for adeno (p < 0.01),
this being due to lower rates (<50) for 1930–60 and
1971–80, and higher rates (>100) for other periods.
Former smokers
The estimated rates shown in Table 13 for former
smokers are lower than the corresponding rates for
current smokers in Table 12. Thus the rates are 198
(177–221, n = 116) for all lung cancer, 78.6 (61.0–101,
n = 28) for squamous and 68.0 (55.7–83.0, n = 28) for
adeno, which are, respectively, 53%, 53% and 67% of
the corresponding estimates for current smokers. As
for current smokers, rates in former smokers were
clearly higher for males than females for all lung cancer
(p < 0.001), squamous (p < 0.001) and adeno (p < 0.05),
with the excess particularly marked for squamous, where
the rate was 144 (121–172, n = 15) in males and 31.2
(18.6–52.4, n = 13) in females.
There was no significant variation (p ≥ 0.1) by region
in all lung cancer rates for former smokers. Limited data
for regions other than the USA made variations by lung
cancer type difficult to assess.
There was evidence of variation by period, due mainly
to a tendency for rates to increase with time, for all
lung cancer (p < 0.001) and adeno (p < 0.05), but not
squamous (p ≥ 0.1).
Meta-regressions
The preceding sections report rates, for a given smoking
status and endpoint, overall and by sex, region and period.
Table 12 Meta-analyses of indirect estimates of lung cancer mortality rates in current smokers
Sex Region Period Statistica All lung cancerb Squamousc Adenod
All All All n 116 28 28
Rate 369.8 (328.0–416.9) 148.8 (114.7–193.1) 102.1 (81.3–128.1)
H,PH 160.43, <0.001 78.07, <0.001 38.44, <0.001
Male n 70 15 15
Rate 546.6 (472.3–632.4) 275.3 (224.1–338.3) 157.5 (120.5–205.7)
Female n 46 13 13
Rate 196.9 (159.1–243.7) 71.9 (54.9–94.2) 59.7 (41.8–85.2)
Betweene PB <0.01 <0.001 <0.05
Canada n 5 2 2
Rate 314.1 (161.0–612.7) 171.8 (36.1–817.1) 118.5 (37.5–374.4)
USA n 40 13 13
Rate 476.7 (390.8–581.5) 150.4 (97.1–233.0) 129.0 (94.6–175.7)
SC Americaf n 8 1 1
Rate 381.5 (290.7–500.5) 131.4 (93.4–185.0) 187.6 (140.3–250.8)
UK n 16 0 0
Rate 406.6 (303.3–545.1)
Scandinaviag n 12 2 2
Rate 381.7 (257.1–566.9) 72.1 (20.5–253.2) 57.7 (20.3–164.0)
W Europeh n 17 5 5
Rate 342.5 (244.0–480.7) 217.0 (156.6–300.8) 59.7 (31.8–111.9)
E Europei n 2 1 1
Rate 425.3 (88.8–2036.7) 413.5 (363.0–471.2) 110.2 (84.5–143.6)
Japan n 9 4 4
Rate 187.0 (133.1–262.9) 101.1 (62.5–163.6) 94.1 (61.3–144.6)
Chinaj n 3 0 0
Rate 285.1 (198.3–410.0)
Other Asiak n 4 0 0
Rate 130.3 (67.3–252.3)
Betweene PB <0.05 NS NS
1930–60 n 10 1 1
Rate 140.6 (112.3–176.0) 33.0 (24.8–44.1) 9.8 (5.9–16.1)
1961–70 n 17 2 2
Rate 331.2 (247.4–443.4) 244.9 (80.4–745.8) 129.1 (97.9–170.2)
1971–80 n 24 4 4
Rate 382.4 (289.5–505.1) 118.9 (36.9–383.4) 38.9 (32.6–46.5)
1981–90 n 49 19 19
Rate 457.4 (393.5–531.6) 157.5 (115.1–215.7) 135.3 (108.9–168.1)
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Table 12 Meta-analyses of indirect estimates of lung cancer mortality rates in current smokers (Continued)
1991–99 n 16 2 2
Rate 400.8 (293.1–548.1) 175.8 (103.7–298.1) 142.1 (83.6–241.7)
Betweene PB <0.001 NS <0.01
a n = number of estimates combined, Rate = random-effects meta-analysis lung cancer mortality rate per 100,000 per year for age 70–74 years (95% CI),
H = heterogeneity per degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.01, p < 0.05, p < 0.1 or NS (p ≥ 0.1), PB = probability
value for heterogeneity between levels (see Methods) similarly expressed.
b All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
c Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
d Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
e Heterogeneity between levels of factor considered.
f Including Argentina, Brazil, Cuba, Uruguay.
g Including Denmark, Finland, Iceland, Norway, Sweden.
h Including Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Spain.
i Including Czechoslovakia, Poland.
j Including China, Hong Kong.
k Including Singapore, South Korea.
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region (China/not China) for never smokers, the tables
and text describing them predominantly concern variation
by sex, region and period considered independently. There
are, however, considerable correlations between the
factors. For example, based on the 220 estimates for ever
or never smoking for all lung cancer, the 59 estimates for
Asia include a higher proportion of estimates for females
(49%) and for 1981–1998 (68%) than is the case for the
161 estimates for other regions, where the proportions are
38% for females and 45% for 1981–1998.
Table 14 presents the results of inverse-variance
weighted regression analyses for never smokers. There is
clear evidence of variation by continent, highly significant
(p < 0.001) for five of the six analyses, and less significant
(p < 0.05) for squamous in males. Rates are similar in
Europe and America, and clearly lower than in China.
Rates in Asia (not China) are also consistently lower
than in China.
For all lung cancer and for adeno, much of the vari-
ability associated with the trend in rate over period can
be explained by adjustment for continent, the timing of
the studies varying by continent. Nevertheless evidence
remains of an increase in the rates over time in each sex
for both endpoints. For squamous, no trend is evident in
males, and in females adjustment for continent made
the estimate negative (−0.21, SE 0.07).
The percentage of the deviance explained by the two
factor model in continent and trend varied between
analyses, from over 80% for all lung cancer and for
adeno in females, to under 25% for squamous in males.
There is no evidence of interaction between the trend
and continent effects for any analysis, and in most of the
analyses there is no evidence that introducing a 10 level
region variable or a 5 level period variable adds signifi-
cantly to the model. The main exception is for all lung
cancer in males. Examination of the estimates (not shown)
showed that this was caused by variation within Europe(high rates in the UK, low in Scandinavia and intermediate
elsewhere), and the tendency for rates to be low in
1930–60 and higher in the other periods with no clear
trend between 1961 and 1999.
Table 15 presents results of inverse-variance weighted
regression analyses for ever smokers. All six analyses
show strong evidence (p < 0.001) of an increasing trend
after adjustment for continent. Although, for all the
analyses for males and for all lung cancer for females,
there is still evidence (p < 0.01 or p < 0.001) of variation
by period given the trend, the additional deviance
explained per degree of freedom by the linear variable is
always substantially greater than that explained by the
departure from trend. For all lung cancer in males, where
the departure is most evident, it is caused by the estimated
rate rising steeply from 1930–60 to 1961–70, then more
slowly to 1981–90 and then falling somewhat.
There is clear evidence (p < 0.01 or p < 0.001) of variation
by continent after adjustment for linear trend for all the
analyses for males and for all lung cancer for females. In
most of these analyses there is also additional evidence of
variation by region within continent. For all lung cancer,
summarizing the findings simply is made more difficult by
the evidence (p < 0.001) of an interaction between trend
and continent, with, in each sex, the slope of the increase
greater in America than in Europe. However, the analyses
confirm the observation made earlier that, whereas for
never smokers rates were consistently higher in China, this
is not so for ever smokers.
Table 16 presents results of inverse-weighted regression
analyses for current and former smokers for all lung can-
cer. There are too few sex-specific estimates for squamous
and adeno to justify further analyses. Although there is no
marked evidence of a trend for former smokers in females,
the other analyses show a clear effect (p < 0.001). In males,
there is also evidence of departure from trend for both
current and former smokers with the rates rising up to
1981–90 and then falling as noted for ever smokers.
Table 13 Meta-analyses of indirect estimates of lung cancer mortality rates in former smokers
Sex Region Period Statistica All lung cancerb Squamousc Adenod
All All All n 116 28 28
Rate 197.7 (177.2–220.6) 78.6 (61.0–101.3) 68.0 (55.7–83.0)
H,PH 35.58, <0.001 36.48, <0.001 16.78, <0.001
Male n 70 15 15
Rate 277.1 (246.4–311.6) 144.3 (121.2–171.8) 91.4 (74.1–112.8)
Female n 46 13 13
Rate 105.1 (87.3–126.6) 31.2 (18.6–52.4) 43.4 (28.4–66.3)
Betweene PB <0.001 <0.001 <0.05
Canada n 5 2 2
Rate 129.5 (64.9–258.5) 52.0 (9.3–289.8) 36.6 (7.9–169.0)
USA n 40 13 13
Rate 230.8 (193.3–275.5) 79.7 (53.9–118.0) 90.9 (72.4–114.2)
SC Americaf n 8 1 1
Rate 216.5 (167.0–280.7) 48.7 (29.0–82.1) 117.6 (84.0–164.8)
UK n 16 0 0
Rate 220.3 (159.1–305.1)
Scandinaviag n 12 2 2
Rate 109.3 (71.8–166.4) 21.0 (3.4–130.6) 15.7 (10.0–24.9)
W Europeh n 17 5 5
Rate 217.1 (165.4–284.9) 160.7 (121.4–212.7) 51.3 (24.6–107.2)
E Europei n 2 1 1
Rate 196.2 (69.4–554.5) 131.0 (96.9–177.1) 56.3 (35.9–88.2)
Japan n 9 4 4
Rate 178.5 (140.4–226.9) 74.0 (43.2–126.6) 96.4 (81.8–113.5)
Chinaj n 3 0 0
Rate 334.4 (276.2–405.0)
Other Asiak n 4 0 0
Rate 72.7 (52.5–100.7)
Betweene PB NS NS <0.1
1930–60 n 10 1 1
Rate 105.0 (72.3–152.4) 19.5 (5.3–71.3) 12.8 (2.8–58.5)
1961–70 n 17 2 2
Rate 152.0 (105.8–218.3) 88.3 (31.3–249.5) 28.0 (9.0–87.1)
1971–80 n 24 4 4
Rate 226.1 (176.4–289.9) 60.1 (18.9–190.6) 25.8 (19.6–33.9)
1981–90 n 49 19 19
Rate 229.7 (198.5–265.8) 80.9 (58.7–111.6) 87.0 (71.2–106.2)
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Table 13 Meta-analyses of indirect estimates of lung cancer mortality rates in former smokers (Continued)
1991–99 n 16 2 2
Rate 193.4 (148.9–251.2) 97.9 (26.2–366.3) 122.3 (104.6–143.1)
Betweene PB <0.001 NS <0.05
a n = number of estimates combined, Rate = random-effects meta-analysis lung cancer mortality rate per 100,000 per year for age 70–74 years (95% CI),
H = heterogeneity per degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.01, p < 0.05, p < 0.1 or NS (p ≥ 0.1), PB = probability
value for heterogeneity between levels (see Methods) similarly expressed.
b All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
c Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
d Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
e Heterogeneity between levels of factor considered.
f Including Argentina, Brazil, Cuba, Uruguay.
g Including Denmark, Finland, Iceland, Norway, Sweden.
h Including Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Spain.
i Including Czechoslovakia, Poland.
j Including China, Hong Kong.
k Including Singapore, South Korea.
Lee and Forey BMC Cancer 2013, 13:189 Page 27 of 36
http://www.biomedcentral.com/1471-2407/13/189Evidence of a variation by continent (given trend) is
strongest for current smokers in males, where rates were
clearly higher in Europe and America than in Asia.
However, there is also variation by region within continent
(p < 0.001), with rates higher in North than in South
America, and in the UK and Eastern Europe than in
Scandinavia or Western Europe. For current smoking
females, rates are highest in America and there is no
evidence of a variation by region within continent. While
there is less evidence of regional variation in former
smokers, it is interesting to note that, in males, region, but
not continent, explained significant (p < 0.01) variation,
with estimates highest for UK and Eastern Europe and
lowest for Scandinavia and Other Asia.
Although for current smokers, the model including
trend and continent explains 66% of the deviance
(in both males and females), there is still evidence
of interaction for females (p < 0.001), due to more
sharply rising trends in America than elsewhere. For
former smokers, the proportion of deviance explained




Our results clearly show that lung cancer rates in never
smokers are markedly higher in China than in other
regions studied. The excess is evident for all lung cancer
and for squamous and adeno. One reason for this may
be the common household use of poorly-vented stoves
in various regions of China. It is interesting to note that
estimates of global mortality attributable to smoking in
2000 published by Ezzati and Lopez in 2003 [19] take
account of variation in the never smoker lung cancer
rate based on household poorly-vented stove use. They
cite evidence of substantial variations in never smoker
lung cancer rates in China as being “largely a result of
patterns of household energy use in China over the pastdecades” with “coal, a common household fuel in China
and traditionally burned in stoves and buildings with
poor ventilation.”
Our results also suggest some tendency for never
smoker overall lung cancer rates to increase over time.
The literature on this issue is not very consistent. Thus,
while no evidence of a trend was seen comparing rates
in the American Cancer Society CPS I and CPS II stud-
ies conducted about 20 years apart [4,20], or comparing
rates by time of follow-up in the US Veterans study [5]
or British Doctors study [6], there have been a number
of reports of an increase in Japan [7,21], Sweden [8],
Italy [22], the UK [23] or the USA [24,25], though some
of the reports suggesting large increases tend to have
clear technical weaknesses and be difficult to interpret
[26]. Any time trend that does exist seems, from our
analyses, to be more evident for adeno than for squamous.
As mentioned later, when we consider the limitations of
our indirect method for estimating lung cancer risks by
smoking habit, there is evidence that this may be associated
with changes over time in categorization of lung cancer
type at diagnosis.
Our results also show some excess of never smoking
lung cancer rates in males for all lung cancer and for
squamous. Although we have excluded estimates from
studies specifically in occupationally exposed groups,
this excess may still be associated with increased exposure
to occupational exposure to carcinogens in males.
Ever smoking rates
The excess in rates for males is more evident for ever
smokers than for never smokers. This is unsurprising in
view of the higher prevalence of smokers in males, their
greater daily cigarette consumption, and their earlier
take up of the habit.
The pattern of variation by region is also very different
for ever smokers and for never smokers. While this
clearly depends on between-regional differences in aspects
Europe































Figure 1 Scatter plot of lung cancer rates in males for never and ever smokers. Table 4 presents indirect estimates of mortality rates
(per 100,000 per year) by smoking habit for all lung cancer in males. The individual study estimates for never smokers (blue diamonds) and ever smokers
(red squares) are plotted against the midpoint year of the study, with separate plots shown for America (Canada, US and South/Central America), Europe


























Figure 2 Scatter plot of lung cancer rates in females for never and ever smokers. Figure 2 is laid out as Figure 1 except that the scale of
the y-axis extends up to 600 rather than up to 900. The individual study estimates are as given in Table 5.





























Figure 3 Scatter plot of lung cancer rates by histological type in males for never smokers. Table 6 (squamous) and Table 8 (adeno)
present indirect estimates of mortality rates (per 100,000 per year) in male never smokers by histological type. The individual study estimates for
squamous (green diamonds) and adeno (orange squares) are plotted against the midpoint year of the study, with separate plots shown for
America (Canada, US and South/Central America), Europe (UK, Scandinavia, West Europe and East Europe), China (including Hong Kong), and


























Figure 4 Scatter plot of lung cancer rates by histological type in females for never smokers. Figure 4 is laid out as Figure 3 except that
the scale of the y-axis extends up to 120 rather than up to 140. The individual study estimates are as given in Tables 7 and 9.



























Figure 5 Scatter plot of lung cancer rates by histological type in males for ever smokers. Table 6 (squamous) and Table 8 (adeno) presents
indirect estimates of mortality rates (per 100,000 per year) in male ever smokers by histological type. The individual study estimates for squamous
(green diamonds) and adeno (orange squares) are plotted against the midpoint year of the study, with separate plots shown for America
(Canada, US and South/Central America), Europe (UK, Scandinavia, West Europe and East Europe), China (including Hong Kong), and Other Asia
























Figure 6 Scatter plot of lung cancer rates by histological type in females for ever smokers. Figure 4 is laid out as Figure 3 except that the
scale of the y-axis extends up to 120 rather than up to 140. The individual study estimates are as given in Tables 7 and 9.
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Table 14 Inverse-variance weighted regression analyses – never smokers
Males Females
All Squamous Adeno All Squamous Adeno
Overall deviance (d.f.) 1525 (128) 196 (42) 254 (42) 2766 (90) 319 (37) 1040 (37)
Drop in deviance and p valuea from including:
Trendb (1 d.f.) 324*** 4 50** 612*** 1 185**
Continentc (3 d.f.) 687*** 47* 127*** 2283*** 205*** 832***
Trend given continent (1 d.f.) 81*** 1 30** 57** 27** 18(*)
Continent given trend (3 d.f.) 445*** 44* 107*** 1729*** 231*** 665***
Residual devianced (d.f.) 756 (124) 148 (38) 97 (38) 426 (86) 87 (33) 190 (33)
Deviance explained 50.4% 24.5% 61.8% 84.6% 72.7% 81.7%
Means (SEs)d:
Constant 4.24 (0.18) 3.74 (0.49) 2.89 (0.43) 4.10 (0.12) 3.77 (0.28) 3.59 (0.31)
Trend 0.15 (0.04) 0.04 (0.11) 0.35 (0.10) 0.09 (0.03) −0.21 (0.07) 0.14 (0.08)
Asia (not China) −0.97 (0.18) −1.44 (0.63) −0.35 (0.31) −0.70 (0.08) −1.28 (0.29) −0.49 (0.15)
Europe −0.42 (0.12) −0.93 (0.35) −1.33 (0.26) −1.04 (0.08) −0.85 (0.19) −1.32 (0.21)
America −0.73 (0.10) −0.83 (0.27) −1.08 (0.19) −1.12 (0.07) −1.38 (0.15) −1.27 (0.12)
Drop in deviance and p valuea from adding:e
10 level regionf (6 d.f.) 103** 37 21 43 28(*) 21
5 level periodg (3 d.f.) 111*** 34* 12 11 10 19
Interactions of trend and continent (3 d.f.) 22 7 15 55 9 7
a p values are coded as *** p < 0.001, ** p < 0.01, * p < 0.05, (*) p < 0.1. If no code is shown p ≥ 0.1. d.f. = degrees of freedom.
b Linear trend in period scoring 1 = 1930–60, 2 = 1961–70, 3 = 1971–80, 4 = 1981–90, 5 = 1991–99.
c Continent defined as China, Asia (not China), Europe or America.
d For model including linear trend in period and continent. Note that estimates for Asia (not China), Europe and America are relative to rates for China.
e Drop in deviance from adding the specific variable to the model including linear trend in period and continent.
f Levels as shown in Tables 10, 11, 12 and 13.
g This tests for departure from linear trend.
Lee and Forey BMC Cancer 2013, 13:189 Page 31 of 36
http://www.biomedcentral.com/1471-2407/13/189of smoking such as prevalence, intensity, duration, extent
of quitting and type of product smoked, it also reflects the
substantially lower relative risk for ever smokers in Asia
highlighted in our first report on the IESLC database [3].
Whereas estimated rates for never smokers in China are
much higher than in other regions, each of the analyses
conducted for ever smoking (by sex and endpoint) give
estimates that are higher than China for a number of
regions of Europe and North America. Rates for ever
smokers for all lung cancer and for squamous seem rather
lower in Scandinavia, Japan, and in parts of Asia other
than China or Japan.
The tendency for rates to increase with time is also
more evident for ever smokers than for never smokers,
and is particularly evident for adeno. The observation
that rates for adenocarcinoma have risen relative to
those for squamous cell carcinoma has been made a
number of times in the literature, the suggestion often
being made [16,27,28] that this is due to changes in the
design of cigarettes. Though this may not be the explan-
ation, inasmuch as there is no evidence of an increased risk
of adenocarcinoma associated with tar reduction or the
switch from filter to plain cigarettes [3,29], our results doindeed suggest that adeno forms an increasingly large part
of overall lung cancer rates over time.
Current and former smokers
Many of the conclusions follow, not unexpectedly, the
results for ever smokers. Thus, for both current and
former smokers, rates are higher in males, and there is
evidence of an increase in rates over time. The pattern
of variation by continent for current smokers is also not
dissimilar from that for ever smokers, with rates highest
in Europe and America for males, and in America for
females. As for ever smoking males, current smoking
males also show evidence of departure from trend and
of interaction between trend and continent, making it
difficult to describe the patterns succinctly. For former
smokers, continent and period explain less of the deviance
than for current smokers. This is likely to be partly due to
the smaller relative risks for former than current smokers,
and the fact that the analyses do not take account of mean
time of quit which will vary by continent (as the timing of
the anti-smoking message was later in Asia than in Europe
or America), and by year (as long-term quitters would
have been less common earlier on).
Table 15 Inverse-variance weighted regression analyses – ever smokers
Males Females
All Squamous Adeno All Squamous Adeno
Overall deviance (d.f.) 42483 (128) 3257 (42) 2618 (42) 6005 (90) 644 (37) 1228 (37)
Drop in deviance (d.f.) and associated p valuea from including:
Trendb (1 d.f.) 14470*** 927*** 1257*** 2425*** 205*** 602***
Continentc (3 d.f.) 6245*** 454 594* 914** 38 224(*)
Trend given continent (1 d.f.) 17056*** 1117*** 1169*** 2278*** 196*** 514***
Continent given trend (3 d.f.) 8831*** 644** 505*** 767*** 29 136*
Residual devianced (d.f.) 19181 (124) 1687 (38) 855 (38) 2813 (86) 410 (33) 490 (33)
Deviance explained 54.9% 48.2% 67.3% 53.2% 36.3% 60.1%
Means (SEs)d:
Constant 4.80 (0.16) 4.57 (0.30) 2.36 (0.41) 3.58 (0.27) 3.12 (0.41) 1.20 (0.60)
Trend 0.27 (0.03) 0.21 (0.04) 0.62 (0.09) 0.51 (0.06) 0.37 (0.09) 0.84 (0.14)
Asia (not China) −0.22 (0.18) −0.51 (0.33) −0.14 (0.30) −0.58 (0.34) −0.72 (0.49) −0.52 (0.49)
Europe 0.67 (0.14) 0.31 (0.28) −0.44 (0.29) −0.37 (0.17) −0.14 (0.29) −0.68 (0.39)
America 0.44 (0.14) 0.23 (0.27) 0.31 (0.25) 0.14 (0.14) −0.19 (0.22) 0.18 (0.24)
Drop in deviance and p valuea from adding:e
10 level regionf (6 d.f.) 6944*** 368 336** 620** 114 84
5 level periodg (3 d.f.) 9002*** 666*** 279** 477** 54 15
Interactions of trend and continent (3 d.f.) 3825*** 78 46 603*** 84(*) 80
a p values are coded as *** p < 0.001, ** p < 0.01, * p < 0.05, (*) p < 0.1. If no code is shown p ≥ 0.1. d.f. = degrees of freedom.
b Linear trend in period scoring 1 = 1930–60, 2 = 1961–70, 3 = 1971–80, 4 = 1981–90, 5 = 1991–99.
c Continent defined as China, Asia (not China), Europe or America.
d For model including linear trend in period and continent. Note that estimates for Asia (not China), Europe and America are relative to rates for China.
e Drop in deviance from adding the specific variable to the model including linear trend in period and continent.
f Levels as shown in Tables 10, 11, 12 and 13.
g This tests for departure from linear trend.
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When considering the results presented, there are a
number of limitations that should be borne in mind.
Considering first the lung cancer mortality data extracted
from the WHO database, one should note that it is only
available for all lung cancer and not by histological type,
and that diagnosis may be inaccurate, with misdiagnosis
rates varying by country and time [30]. Although the
definition of lung cancer under the various revisions of
the ICD relevant to this report are essentially unchanged,
coding practices may have varied. Excessive use of codes
for ill-defined and unknown causes and incomplete death
registration coverage may have detracted from the quality
of the data, with only 33% of relevant countries recently
assessed as providing “high quality” data [31]. For some
countries, data relate only to selected regions (Table 1),
with data for China derived from a sample registration
scheme including less than 10% of all deaths occurring in
the country [1].
Furthermore, though survival rates remain very poor,
trends in mortality may not necessarily reflect trends in
disease incidence. Cancer incidence rates are available, but
for a far narrower range of countries and time periods.There are also a number of limitations with the data
on relative risk by smoking habit obtained from the
IESLC database. These include variations in definition of
smoking, definition of disease and extent of adjustment
for confounders, and bias due to misclassification of
smoking status. These and some other issues are also
discussed in the first paper on IESLC [3], but some of
the principal points are considered below.
As regards definition of smoking, relative risks
were selected for smoking of any product, if available,
and of cigarettes (or cigarettes only) otherwise. In
countries where pipe and cigar smoking is rare, this
distinction may be of little consequence, but it may be
more important in some countries. The type of
cigarette smoked is also relevant, and though no clear
difference in risk has been noted between the flue-
cured cigarettes smoked in the UK and various other
(mainly Commonwealth) countries [2,32] or between
mentholated and unmentholated cigarettes [33], there
is clear evidence that risk is greater in handrolled than
manufactured cigarettes [29], in black than blond tobacco
cigarettes [34], and in higher tar plain cigarettes than
in lower tar filter cigarettes [35].
Table 16 Further inverse-variance weighted regression analyses for all lung cancer
Current smokers Former smokers
Males Females Males Females
Overall deviance (d.f.) 14399 (69) 2926 (45) 2523 (69) 611 (45)
Drop in deviance (d.f.) and associated p valuea from including:
Trendb (1 d.f.) 5136*** 1490*** 485*** 56*
Continentc (3 d.f.) 2981** 989*** 173 148**
Trend given continent (1 d.f.) 6544*** 928*** 491*** 33(*)
Continent given trend (3 d.f.) 4389*** 427** 178 126*
Residual devianced (d.f.) 4875 (65) 1009 (41) 1860 (65) 430 (41)
Deviance explained 66.1% 65.5% 26.3% 29.6%
Means (SEs)d:
Constant 4.43 (0.41) 3.18 (0.64) 5.02 (0.65) 4.68 (0.85)
Trend 0.36 (0.04) 0.57 (0.09) 0.21 (0.05) 0.26 (0.15)
Asia (not China) −0.13 (0.41) −0.37 (0.62) −0.47 (0.67) −0.79 (0.80)
Europe 1.09 (0.39) 0.01 (0.56) 0.02 (0.62) −1.49 (0.67)
America 0.80 (0.39) 0.61 (0.53) 0.16 (0.62) −0.52 (0.61)
Drop in deviance and p valuea from adding:e
10 level regionf (6 d.f.) 2274*** 237 539** 55
5 level periodg (3 d.f.) 1658** 181(*) 647*** 34
Interactions of trend and continent (3 d.f.) 370(*) 402*** 111 46
a p values are coded as *** p < 0.001, ** p < 0.01, * p < 0.05, (*) p < 0.1. If no code is shown p ≥ 0.1. d.f. = degrees of freedom.
b Linear trend in period scoring 1 = 1930–60, 2 = 1961–70, 3 = 1971–80, 4 = 1981–90, 5 = 1991–99.
c Continent defined as China, Asia (not China), Europe or America.
d For model including linear trend in period and continent. Note that estimates for Asia (not China), Europe and America are relative to rates for China.
e Drop in deviance from adding the specific variable to the model including linear trend in period and continent.
f Levels as shown in Tables 10, 11, 12 and 13.
g This tests for departure from linear trend.
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definition of all lung cancer, squamous and adeno.
While for the great majority of studies the definitions
include, respectively, all cases, only cases of squamous cell
carcinoma, and only cases of adenocarcinoma, in a small
number of studies alternative definitions were allowed.
Thus, for all lung cancer our definitions also includes (i) all
cases other than alveolar cell cancer, (ii) all cases except
lung cancers of mixed cell types, (iii) only cases of
squamous cell carcinoma and adenocarcinoma, (iv) as
definition (iii) but also small cell carcinoma, and (v) as
definition (iv) but also large cell carcinoma. Definitions
of “squamous” also included (i) Kreyberg I lung cancers, (ii)
all lung cancers except adenocarcinoma, and (iii) squamous
cell and differentiated carcinomas and (iv) squamous
cell and small cell carcinomas. Definitions of “adeno”
also include Kreyberg II lung cancers, (ii) adenocarcin-
omas and large cell carcinomas, (iii) all lung cancers
except squamous cell and undifferentiated carcinomas, and
(iv) all lung cancers except squamous cell and small cell
carcinomas. While it would have been possible to make
the data “purer” by omitting such alternative definitions
(and also only allowing data for smoking of any product),this would have reduced the number of studies available,
and lost power.
A related issue is change over time in the diagnosis of
lung cancer types. Though it is generally recognized that
the relative frequency of adenocarcinoma to squamous
cell carcinoma has changed over time (e.g. [16,36]),
there are reports [37,38] of studies which re-evaluated
diagnoses conducted in previous years, finding that
many lung cancers initially considered to be squamous
cell carcinomas should, according to more modern criteria,
be considered adenocarcinomas.
Although we preferred to use unadjusted relative risks
as being directly relevant to the national mortality rate,
we did include adjusted relative risks for squamous and
adeno due to the scarcity of unadjusted data. This is
unlikely to have had any major effect as we previously
demonstrated that adjustment had little effect on the
relative risks [3].
The issue of misclassification of smoking status is
perhaps more serious. Some years ago, we carried out
extensive work on the misclassification of smoking
status and the effect it has in biasing the estimates of
the association between environmental tobacco smoke
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calculations we assumed that, in Western populations,
the bias may be equivalent to that caused by 2.5% of
average lung cancer risk ever smokers reporting that
they have never smoked. For Asian populations, the
percentage is clearly higher (see e.g. [43]), perhaps 10%
or 20%. If these rates apply, and there are considerable
uncertainties [39,44], misclassification will have a
marked effect on the estimated lung cancer death rates
in never smokers.
To illustrate this, consider a population in which 50%
have ever smoked, and in which the true relative risk for
ever vs never smoking is 8. Suppose also that the overall
lung cancer death rate is 45. Based on these “true” data,
the indirect estimates of rates by our method would be
10 in never smokers and 80 in ever smokers. If in fact
2.5% of ever smokers are misclassified as never smokers,
one can then readily show that one will observe 48.75%
to have smoked, and a relative risk of 6.83. Based on the
“observed” data, the estimated rates will then still be 80
in ever smokers but will be 11.7, not 10, in never
smokers. For misclassification rates of 10% and 20%, the
estimated rates in never smokers will be higher still,
respectively, 16.4 and 21.7, corresponding to “observed”
relative risks of 4.89 and 3.69. The extent of the bias
increases, not only with the misclassification rate, but
also with the true proportion of ever smokers.
Other limitations concern combining the relative risk
data from IESLC with the national rates from WHO.
One relates to the fact that most of the relative risk
estimates derive from studies that are not nationally
representative but are drawn from populations of a
variety of types. We have sought to minimize this
problem by excluding studies conducted in populations
that were grossly unrepresentative, as described in the
Methods section. Relative risks based on a variety of
populations are frequently subject to meta-analysis in an
attempt to get an overall average risk which can be taken
to apply generally, and our use of relative risks derived
from somewhat unrepresentative populations involves
essentially the same underlying assumption.
Lack of national representativeness of the IESLC study
populations will also mean that the estimated distribution
of smoking habits may not be the same as that seen in the
country where the study was conducted. If the at risk
population in a cohort study (or the control population in
a case-control study) contains too low a proportion of
ever smokers, national rates in both ever and never
smokers will be overestimated, and if it contains too high
a proportion they will be underestimated. For example,
assuming that the relative risk is 9, the national lung cancer
rate is 100 and the national population actually contains
50% ever smokers, the true rates of 20 in never smokers
and 180 in ever smokers will be estimated as 23.8 and214.3 if the control/at-risk population contains 40% ever
smokers, and as 17.2 and 155.2 if the population contains
60% ever smokers. Such biases seem unlikely to affect our
conclusions, as they seem much smaller than the marked
differences seen by region and period. In any case it is
unclear why such biases should cause spurious regional
differences or trends.
Another issue relates to which WHO 5 year period
data to use for a given study. For case-control studies we
use the midpoint year of the interviews, while for
prospective studies, we use a survival-adjusted mid-point
of the follow-up period. Although both are open to
question, this is unlikely to cause any major error. Nor
is the use of substitute years (see Table 1). The need for
this was relatively rare, and sometimes involved only
quite small differences in time.
A major feature of our methodology is that it applies
all age relative risks from studies based on populations
of varying ages to estimate lung cancer rates by smoking
habit for age 70–74, based on overall WHO rates for
that age group. This issue is discussed in the Methods
section “Testing the validity of the method with respect
to age”. This gives justification for our decision to select
age 70–74 rather than any other age range, and points
out that studies of young populations were excluded from
consideration. It should also be noted that age-specific data
on lung cancer relative risks are very limited, and even then
are not for five year age groups. Any weaknesses resulting
from the decision to use age 70–74 rates seem likely to
apply similarly in the various studies considered, and
should therefore not affect conclusions regarding variations
by sex, region and time period.
We should also point out that our meta-regressions
are relatively limited. Better understanding of patterns in
rates over time and region may be gained by additional
analyses which take into account aspects of the studies
used to generate the rates. The relevant data for
others to attempt this are available from the Tables in
this report and from our original paper based on the
IELSC database [3].
Conclusions
Data on lung cancer mortality rates by smoking habit are
not available nationally, and studies presenting estimates
are quite limited in scope, particularly for current and
former smokers, and by histological type. This deficiency
can hinder interpretation of the evidence on factors
associated with lung cancer risk, a deficiency we have tried
to rectify using an indirect estimation method. Estimates
of absolute rates by country, sex, smoking habit and
histological type were derived from 148 epidemiological
studies by linking their findings to WHO national lung
cancer mortality data. There are a number of potential
limitations of the method, due to such factors as variations
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epidemiological database, changes over time in diagnosis of
lung cancer types, lack of national representativeness of
some studies, and regional variation in smoking misclassifi-
cation rates. However many features of the results are
consistent with the epidemiological literature. These
include the high never smoker lung cancer rates in China,
the increasing trend in rates over time in smokers, and the
tendency for adeno rates to rise relative to squamous rates.
This gives some confidence in the results, and suggests that
other conclusions to be drawn from the indirect rates have
validity. For example, the observation that, over the
period 1930–2000, estimated rates for adeno among
never smokers have risen markedly compared to the
corresponding rates for squamous, strongly suggests
that changes in the type of cigarette smoked are unlikely
to explain the marked increase in the relative frequency
of adenocarcinoma to squamous cell carcinoma.
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